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ABSTRACT

Chlamydophila psittaci causes severe disease in birds and humans, and important
economical losses in the avian companion and poultry industry. Vaccines are the most costeffective measure to control and help prevent infectious diseases, but to date there is no
commercial vaccine available. A randomized clinical trial was conducted to assess the efficacy
of two recombinant DNA vaccines against C. psittaci in Cockatiels (Nymphicus hollandicus).
The first recombinant DNA vaccine has a gene encoding MOMP and the immunostimulant
chitosan (MOMP DNA vaccine). The second recombinant DNA vaccine, contained the gene
encoding MOMP that was vectored by a replication defective human adenovirus (adeno-MOMP
vaccine). Forty adult cockatiels (Nymphicus hollandicus) were used for this study, and divided
into each of the vaccinated groups (n=10), positive control (n=10) and a negative control (n=10).
The animals were vaccinated on days 0 and 21 with the corresponding vaccine (DNA MOMP
vaccine group, adeno-MOMP vaccine group, negative control group) or placebo (positive
control group), and both vaccine groups and the positive control were challenged on day 42
Receiving 0.1 ml of inoculum IN containing approximately 106 C. psittaci live organisms. The
negative control group was not challenged with any live organisms. The animals were monitored
daily for the presence of rhinitis, conjunctivitis, dyspnea, diarrhea and depression. On days 46,
49, 52, 55, 70 and 82, combined choanal and cloacal swabs were taken and submitted for C.
psittaci PCR. The surviving birds were tested on day 82 for antichlamydial antibodies (IFA) and
for the presence of C. psittaci (PCR) from whole blood and combined choanal-cloacal swabs,
and then humanely euthanized. The birds were submitted for necropsy and examined for the
presence of macroscopic lesions on conjunctiva, lungs, airsacs, heart, spleen and liver.
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Individual samples from each of those tissues were taken for histopathology and pooled samples
were submitted for C. psittaci culture.
There was a failure to detect antibody response by indirect immunofluorescent assay.
The cockatiels developed mild clinical signs and minimal mortality after challenge. The
necropsy and histopathologic evaluation of the tissues revealed mild to moderate lesions and
no significant difference with positive control. Further studies are needed to evaluate the
efficacy of the vaccines.
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CHAPTER ONE
INTRODUCTION
Avian chlamydiosis is caused by Chlamydophila psittaci, a Gram-negative obligate
intracellular bacteria. Avian chlamydiosis was previously named psittacosis, or parrot fever, as
the diseases was originally recognized in psittacine birds and in humans in contact with these
birds (Morange 1895). Avian chlamydiosis was also named ornithosis, to refer to chlamydial
disease in, or contracted from, domestic poultry and free-ranging birds other than psittacine birds
(Meyer 1941). Currently these terms are considered to be the same, and the preferred term is
avian chlamydiosis (Page 1984).
C. psittaci has a wide range of avian hosts (Kaleta and Taday 2003) and can also infect
mammals including humans, reptiles, amphibians, fish and invertebrates (Vanrompay, Ducatelle
et al. 1995). The clinical signs are variable, and commonly involves the respiratory,
gastrointestinal, nervous and ocular systems (Gerlach 1994). The antemortem diagnosis of
avian chlamydiosis is difficult, and a combination of different diagnostic test is recommended
(Vanrompay 2000). The lesions are variable and the post-mortem diagnosis of chlamydiosis
depends on the demonstration of chlamydial organisms or chlamydial antigens in typical lesions
by histochemical and immunohistochemical techniques (Graham 1993). C. psittaci infections
represent important economical losses in the avian companion and poultry industry, since the
general public, poultry workers and veterinary surgeons are at risk of illness from this zoonotic
agent (Andersen and Vanrompay 2000).
Vaccines constitute the most effective method for preventing disease. DNA vaccines
present several advantages over conventional vaccines, and some of them are especially
important in developing potential effectors of long term cell mediated anti-chlamydial immunity
(Oshop, Elankumaran et al. 2002). DNA vaccine candidates against C. psittaci infection have
1

shown promising results (Tully TN 1997; Vanrompay, Cox et al. 1999; Vanrompay, Cox et al.
1999; Vanrompay, Cox et al. 2001; Verminnen, Loock et al. 2005; Loots, Loock et al. 2006;
Loots, Vleugels et al. 2006; Zhou, Qiu et al. 2007). These recombinant DNA vaccine candidates
have used the major outer membrane protein (MOMP) A (ompA or omp1) gene to induce
protective immunity against C. psittaci infections. The MOMP is a immunodominant protein
isolated from chlamydial elementary bodies, carrying genus-, species, and serovar-specific
epitopes (Vanrompay, Vanloock et al. 2001). DNA vaccines delivery can be improved by the use
of virus as a vector (Bostock 1990). Adenoviruses are highly efficient at delivering genetic
material into a broad range of cell types, producing a sustained and specific cellular response
without becoming integrated into the host genes (Babiuk and Tikoo 2000). DNA vaccine
absorption can be improved through the use of absorption enhancers (Davis and Illum 2003).
Chitosan, a polysaccharide, improves delivery of DNA through mucoadhesion, enhancement of
mucosal epithelial permeability, the formation of nanoparticles that protect and control the
release of DNA and enhancement of local and systemic immune responses (Senel 2004).
The objective of this study was to assess the efficacy of two recombinant DNA
vaccines against C. psittaci in cockatiels (Nymphicus hollandicus). The first recombinant DNA
vaccine has a gene encoding MOMP and the immunostimulant chitosan (MOMP DNA
vaccine). The second recombinant DNA vaccine, containins the gene encoding MOMP that is
vectored by a human adenovirus (adeno-MOMP vaccine).
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CHAPTER TWO
LITERATURE REVIEW
2.1 Avian Chlamydiosis
2.1.1 Etiology
The Chlamydiaceae family has two genera and nine species. The genus Chlamydia
includes C. trachomatis, C. muridarum, C. suis, while the genus Chlamydophila includes C.
abortus, C. caviae, C. felis, C. pecorum, C. pneumoniae and C. psittaci. Analysis of
phylogenetic markers (16S-23S rRNA intergenic spacer region) by PCR-restriction fragment
length polymorphism (RFLP) and PCR-sequence, provides a rapid and reproducible method for
identifying and classifying organisms within the Chlamydiaceae family (Everett and Andersen
1997; Everett, Bush et al. 1999; Andersen and Vanrompay 2000; Sudler, Hoelzle et al. 2004).
Chlamydophila psittaci is classified into at least nine genotypes by PCR-sequencing the
ompA gene encoding the major outer membrane protein, PCR-RFLP analysis of the ompA gene,
or by genotype-specific real-time PCR . (Sayada, Andersen et al. 1995; Vanrompay, Butaye et
al. 1997 ; Hoelzle, Steinhausen et al. 2000; Geens, Desplanques et al. 2005; Geens, Dewitte et al.
2005). Seven of these genotypes (A-F and E/B) have been isolated primarly from birds. The
genotype E/B generates the RFLP pattern characteristic for genotype E. However, it differs from
genotype E and B by a unique combination of guanosisne and cystidine residues. Genotype E/B
can only be distinguished from genotypes E and B by omp A sequencing or by genotypespecific real-time PCR (Geens, Desplanques et al. 2005).
The three morphologically distinct forms of C. psittaci are termed elementary body (EB),
reticulate body (RB) and intermediate body (IB) (Andersen and Vanrompay 2003). The EB is
the infectious form, and attaches to the cells, penetrates and becomes the RB. The EB is a small,
electron dense, spherical body, measuring 0.2-0.3 µm in diameter. The EB is characterized by a
3

highly electrodense nucleoid, located at the periphery and clearly separated from a electro-dense
cytoplasm. The RB is the intracellular form, and measures 0.5-2.0 µm in diameter. The IB are
morphologically intermediate forms between the RB and EB observed inside of the host cell,
measuring 0.3-1.0 µm in diameter. The IB has a central electron-dense core with radially
arranged individual nucleoid fibers surrounding the core (Andersen and Vanrompay 2003).
C. psittaci has a cytoplasmic membrane and an outer membrane. The outer membrane is
composed of phospholipids, lipids, lipopolysacharides, glycolipids, and proteins, but as a gramnegative bacteria, no muramic acid has been detected in chlamydiae (Vanrompay 2000).
The major outer membrane protein (MOMP) has a molecular weight of 40kDa and
represents approximately 60% of the weight of the outer membrane. The MOMP has been
isolated from the elementary bodies (Gerlach 1993). MOMP is an immunodominant protein
carrying genus-, species, and interestingly serovar-specific epitopes (Vanrompay, Vanloock et al.
2001). The outer membrane protein A (ompA or omp1) gene encodes the MOMP. The ompA
gene contains 5 conserved and 4 variable sequence regions, VS1 to VS4, which encode for the
variable protein domains VDI to VDIV(Andersen and Vanrompay 2003). Genus and speciesspecific antigenic determinants are found within the conserved regions, but also have been found
in the more conserved parts of VDIV. Serovar-specific antigen are located within VDI and VDII
(Conlan, Clarke et al. 1988; Andersen and Vanrompay 2003). Genus, species and serovar
specific epitopes are identified by the use of monoclonal antibodies (MAbs) (Toyofuku,
Takashima et al. 1986; Fukushi, Nojiri et al. 1987; Andersen and Van Deusen 1988; Seki,
Takashima et al. 1988; Takahashi, Takashima et al. 1988; Andersen 1991; Kikuta, Furukawa et
al. 1991; Kunz, Pospischil et al. 1991; Ando, Takashima et al. 1993; Herring 1993; Vanrompay,
Andersen et al. 1993; de Sa, Souriau et al. 1995; Duan, Souriau et al. 1999; Andersen 2005).
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Using serovar specific MAbs, C. psittaci strains are classified into serovars. Six of these serovars
have been isolated primarly from birds (A-F) (Andersen 1991; Vanrompay, Andersen et al.
1993; Andersen 1997; Duan, Souriau et al. 1999; Hoop, Schiller et al. 2002; Andersen 2005).
These six serovars (A-F) correspond to the seven previously described genotypes (A-F and
E/B) (Vanrompay, Butaye et al. 1997 ; Geens, Dewitte et al. 2005). The genotype E/B reacts
with both the serovar E- and B-specific mAbs (Geens, Dewitte et al. 2005).
The different antigens characterized in the EB are chlamydial LPS of 10 kDa ; a 40 kDa
MOMP ; a 57 kDa outer membrane protein believed to be a member of the family of the heat
shock proteins; a 60 kDa surface exposed heat shock protein (hsp60); a 60 kDa cysteine-rich
outer membrane protein (crp60); a 62 kDa surface exposed protein , and finally a 97.4 kDa outer
membrane protein (Verminnen, Van Loock et al. 2006). The antigenic chlamydial proteins
characterized in infected cells but not detected in the purified EBs are p22, p34, and p52, of 22,
34 and 52 kDa respectively. The proteins p34 and p52 were each detected in RBs, while p22 was
not detected in purified RBs (Rockey and Rosquist 1994).
The chlamydial lipopolysaccharide (LPS) is a major component and antigen of the outer
membrane, and is present in both the EB and the RB (Andersen and Vanrompay 2003). The LPS
has a molecular weight of 10 kDa. The LPS contains Chlamydiaceae and species-specific
antigens determinants detectable by monoclonal antibodies (Thiele, Karo et al. 1992; Ando,
Takashima et al. 1993; Brade, Rozalski et al. 2000; Muller-Loennies, Gronow et al. 2006), and
several antigen determinants cross-react with the LPS of certain gram-negative bacteria
(Nurminen, Wahlstrom et al. 1984; Haralambieva, Iankov et al. 2001). The heat shock protein
60 (hsp60) has genus and species-specific epitopes that cross-react with other gram negative
bacteria.(Yuan, Lyng et al. 1992). The presence of cross-reactive epitopes on the chlamydial
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outer membrane shoud be considered when choosing or interpreting a specific diagnostic test
(Andersen and Vanrompay 2003).
2.1.2 Hosts
C. psittaci has a wide range of avian hosts. The most recent list of avian species that
have been tested positive includes 469 species comprising 30 orders (Kaleta and Taday 2003).
The order Psittaciformes contains by far the most susceptible species (153 of 342; 45%), then the
orders Lariformes (gulls, 26 of 92 species; 28%), Alciformes (alks, six of 23 species; 25%),
Sphenisciformes (penguins, 4 of 16 species; 25%), Anseriformes (ducks and geese, 33 of 157
species; 21%), and finally the order Phasianiformes (gallinaceous birds, 14 of 259 species; 5%).
C. psittaci can also infect mammals including humans (both all domesticated and many free
ranging), reptiles, amphibians, fish and invertebrates (Vanrompay, Ducatelle et al. 1995) .
2.1.3 Developmental Cycle
The propagation cycle of C. psittaci as described (Gerlach 1994):
Step 1. The first step in replication is the attachment to and penetration of a target cell (mainly
columnar epithelial cells of mucous membranes and mononuclear macrophages) by the
infectious-toxic but nonpropagating EB. The process is comparable to receptor-mediated
endocytosis. The chlamydia is enveloped in an endocytoplasmic vesicle where it remains
throughout the replication cycle. By remaining in an endosome, the chlamydia is protected from
host-derived lysozymes. The development of a phagolysosome (which would destroy the
engulfed organism) is inhibited by chlamydial-derived proteins.
Step 2. The second phase of replication is the transition of the metabolically inert elementary
body into the larger, fragile, low density, metabolically active reticulate body. This phase of the
replication cycle probably begins with the reduction of the disulfide bond that cross links the
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outer membrane proteins. The developing reticulate bodies possess several surface projections
that are assumed to protrude through the endosomatic membrane to enable
the uptake of nutrients from the host cytoplasm. In other respects, the reticulate bodies resemble
bacterial L-forms (which have defective cell walls), because they can persist despite circulating
antibodies and therapies designed to inhibit cellular wall formation.
Step 3. The growth and binary fission of the reticulate bodies result in the production of many
progeny and micro-colonies containing from 100 to 500 chlamydial organisms per cell. Multiple
micro-colonies, also called “inclusions” (Levinthal-Cole-Lillie = LCL bodies) can occur in an
infected cell. By the end of the replication cycle, enzymes produced by the intracellular
bacteria may induce lysis of the host cell (48 hours after the initial infection). These enzymes are
susceptible to antibiotics. Endotoxicosis may occur in the host cell when lysosomes are
destroyed and endosomatic enzymes are released into the cytoplasm.
Step 4. Maturation of the noninfectious reticulate bodies into infectious elementary bodies
involves the restoration of the surface membrane and its associated toxicity. Chlamydia
lipopolysaccharide is brought to the host cell surface concomitantly with the growth of
chlamydial organisms. This glycolipid is assumed to stabilize the plasma membrane, thereby
protecting the chlamydial-infected cells from cytotoxic T-cells.
Step 5. Newly formed elementary bodies are released, not always by lysis of the host cell.
The whole cycle can require 48 to 72 hours, depending on infecting strain, host and
environmental conditions.
However, the classical hypothesis of a lytic biphasic cycle seems to reflect only
optimized growth conditions and needs to be extended by persistence as a third state (Hogan,
Mathews et al. 2004). Chlamydial persistence is known as a state of infection during which the
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pathogen remains viable but noncultivable, while the host immune system is incapable of
eliminating it (Beatty, Morrison et al. 1994). Morphologically, this reversible state is
characterized by aberrant bodies, i.e., enlarged pleomorphic RBs, and reduced inclusion size
(Goellner, Schubert et al. 2006).
2.1.4 Epidemiology
C. psittaci serovars are relatively host specific (Andersen 1991; Vanrompay, Andersen et
al. 1993; Andersen 1997; Duan, Souriau et al. 1999). Serovar A is endemic among psittacines.
Genotype B is endemic among pigeons. Serovar C is most frequently associated with water
fowl, but has been isolated from a partridge and a turkey. Serovar D is often associated with
turkeys, but has been also isolated from egrets and seagulls. Serovar E have been isolated from
ducks, pigeons, ostriches and rheas. Serovar F was first obtained from a parakeet (Andersen
1997) and eight years later from a Belgian fattening turkey (Van Loock, Geens et al. 2005)
Avian chlamydiosis occurs worldwide (Andersen and Vanrompay 2000). Different
studies have been published regarding the prevalence of C. psittaci infections in free-ranging
birds (Fukushi, Itoh et al. 1983; Ruppanner, Behymer et al. 1984; Bracewell and Bevan 1986;
Miyake, Morishita et al. 1986; Brand 1989; Salinas, Caro et al. 1993; Astorga, Cubero et al.
1994; McElnea and Cross 1999; Raso Tde, Junior et al. 2002; Travnicek, Cislakova et al. 2002;
Padilla, Huyvaert et al. 2003; Padilla, Santiago-Alarcon et al. 2004; Deem, Noss et al. 2005;
Prukner-Radovcic, Horvatek et al. 2005; Heddema, Ter Sluis et al. 2006). Outbreaks of avian
chlamydiosis causing deaths in free-ranging birds have also been described (Grimes 1966;
Gough and Bevan 1983; Simpson and Bevan 1989; Franson and Pearson 1995). Studies have
been published as well regarding prevalence and outbreaks in captive birds, including companion
animals, zoological collections and poultry (Page 1976; Wachendorfer 1984; Chalmers, Farmer
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et al. 1985; Bracewell and Bevan 1986; Moore, Petrak et al. 1988; Newman 1989; Fowler,
Schulz et al. 1990; Greth, Andral et al. 1993; Grimes, Small et al. 1997; Vanrompay, Butaye et
al. 1997; McElnea and Cross 1999; Celebi and Ak 2006; Harkinezhad, Verminnen et al. 2007;
Matsui, Nakashima et al. 2007). The methodology and results of these epidemiologic studies
have been highly variable.
Horizontal transmission, from one infected bird to another is the primarly form of
transmission. The route of infection is inhalation of airborne chlamydiae or ingestion of
contaminated material (Andersen and Vanrompay 2000). Chlamydia organisms are shed
regularly or intermittently in the feces (up to 105 infectious units per gram of feces), urine,
lacrimal fluid, nasal discharge, mucous from the oral and pharyngeal cavities and “crop milk”
(pigeons) of infected birds (Gerlach 1994). Arthrophod vectors have been shown to transmit
chlamydiae in turkeys, but probably act as a mechanical vector rather than biological vector
(Shewen 1980). Vertical transmission of chlamydiae was described in chickens, ducks,
parakeets, sea gulls and snow geese (Vanrompay, Ducatelle et al. 1995)
2.1.5 Pathogenesis
The pathogenesis of avian chlamydiosis have been studied in psittacines (Rivers, Berry
et al. 1931; Jacoby and Gerbermann 1982; Tappe, Andersen et al. 1989), turkeys (Page 1959;
Beasley, Davis et al. 1961; Tappe, Andersen et al. 1989; Vanrompay, Mast et al. 1995) and
chickens (Takahashi, Takashima et al. 1988). Many factors such as species, age, immune
status, route of exposure, and the C. psittaci strain contribute to the pathogenesis of avian
chlamydiosis (van Buuren, Dorrestein et al. 1994).
In the natural host species, the associated chlamdydial serovar produces a long-term
infection (Tappe, Andersen et al. 1989). The virulence and toxicity of host adapted strains can
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be most dramatic when they infect a different species (Gerlach 1994). These differences are
reflected in the number and type of affected tissues and replication rate as determined by the
period necessary for elementary bodies to appear (Jacoby and Gerbermann 1982).
In Amazon parrots inoculated with serovars A, B, C and D, long-term infection and later
clinical signs were seen with serovar A while the other serovars (B, C and D) caused earlier
clinical signs and serovar D caused an increase in mortality (Jakoby 1981).
In turkeys, serovar D characteristically induced severe pericarditis; air saccuitis was
less severe than that seen following infection with a psittacine isolate, and clinical disease
usually developed after a longer incubation period. Serovar A in turkeys caused marked
airsacculitis and bronchopneumonia, but only mild pericarditis with associated low mortality
(Andersen and Tappe 1989). Serovar D produces a morbidity of 50-80% and mortality of 5-30%
or higher. With infected turkeys, the strains of low virulence (serovars A, B and E) usually have
low morbidity rates (5%-20%) and mortality (1-4%) rates (Andersen and Vanrompay 2000).
With pigeons and sparrows species, the psittacine strains induce a typical infection
resulting in a mild clinical signs; the turkey isolates have little or no effect (Andersen and Tappe
1989).
Young birds are generally more susceptible to infections than adults (Gerlach 1994).
Adult chickens were considered to be resistant to overt disease associated with C. psittaci
infection (Takahashi, Takashima et al. 1988), and C. psittaci organisms were recovered more
frequently in younger birds (Bankowski, Mikami et al. 1967; Bankowski, Gerlach et al. 1968).
Within Psittaciformes, New world species (e.g., macaws, Amazon parrots) appear to be
more susceptible than Old world species from Africa, Australia and Asia (e.g., African grey
parrots, cockatoos, lories) (Gerlach 1994). These are generalizations with many exceptions, and
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the condition of a host is probably more important than any species specific susceptibility
(Gerlach 1994).
When virulent strains of chlamydia are inhaled, primary propagation occurs within the
epithelial cells of the lung and air sacs (Gerlach 1994). From studies on turkey infected by
aerosol the following pathogenic sequence could be deducted for serovar D: infection of the
lungs, airs sacs and pericardial sac within 4 hours; within 48 hours, chlamydiae were present in
the blood , spleen, liver and kidney; at 72 hours in the bone marrow, testes or ovaries and
muscle (Page 1959). If chlamydial organisms are ingested, they are believed to initially replicate
within the intestinal tract (Gerlach 1994).
2.1.6 Clinical Signs
The incubation period for C. psittaci is difficult to determine because of differences in
strain virulence, varying clinical responses of a wide avian host range and the chronic infections
that can occur in some hosts (Gerlach 1994). Experimentally, clinical signs of disease may be
evident in 5-10 days in turkeys receiving a virulent strain (Andersen and Vanrompay 2003).
Natural infection in older birds, exposed to smaller doses or receiving less virulent strains, may
have longer incubation periods and clinical signs may not be noticeable until 2-8 weeks after
exposure (Andersen and Vanrompay 2003).
There are no pathognomonic signs of avian chlamydiosis and the disease is easily
confused with common bacterial and viral infections (Flammer 1997). The clinical signs of avian
chlamydiosis have been described in psittacine species (Rivers, Berry et al. 1931; Gerlach 1994),
pigeons (Hughes 1947; Andersen and Vanrompay 2003), turkeys (Vanrompay, Ducatelle et al.
1995; Andersen and Vanrompay 2003), ducks (Arzey, Arzey et al. 1990), chickens (Arzey and
Arzey 1990), ratites (Pericard and al 1991). Subclinical infections are characteristic in adult
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birds exposed to moderate numbers of a moderately virulent strain of C. psittaci. These infected
birds may shed the organism for several months while exhibiting minimal signs of clinical
disease. Extreme environmental changes or concurrent infections may activate persistent
infections through stress and subsequent immunosupression, resulting in clinical disease
(Gerlach 1994).
The clinical signs associated with avian chlamydiosis varies with the presentation: acute,
subacute and chronic (Gerlach 1994). Acute presentations are typical of young birds exposed to
virulent strains and clinical signs can include rough plumage, low body temperature, tremor,
lethargy, conjunctivitis, dyspnea, rales, and sinusitis. Emaciation, dehydration, greenish
droppings (suggesting liver involvement), or grayish, watery droppings may also be noted. Death
ensues within 8 to 14 days. Spontaneous recovery is rare and survivors may have poorly formed
feathers (Gerlach 1994). Subacute or protracted presentations are typical for all avian species
with a reduced susceptibility or for those infected with a moderately virulent strain and
progressive emaciation, greenish diarrhea, occasional conjunctivitis and high levels of urates in
the droppings are common. Occasionally development of central nervous system signs,
including paroxysmal or continuous clonic-tonic convulsions, tremors and opisthotonos as well
as flaccid paralysis may occur. Birds die within a few weeks if they are not treated (Gerlach
1994).
In addition to the classic signs of avian chlamydiosis described earlier, certain
syndromes are common among some groups of birds (Flammer 1997): 1) reduced egg
production, low hatchabiliy, and nestling mortality are common complaints in avicultural
collections of cockatiels and budgerigars; 2) Amazon parrots frequently have green-stained
urine, indicative of biliverdinuria due to hepatic dysfunction; 3) Macaws may show only lower
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respiratory signs, characterized by severe dyspnea; 4) Cockatoos may show chronic wasting and
other general and inespecific clinical signs, but they also may become subclinical shedders.
2.1.5 Diagnosis
The methods used to diagnose C. psittaci infections are 1) direct visualization of the
agent in clinical specimens by staining techniques, 2) isolation of the agent from clinical
specimen followed by identification of the isolated agent, 3) detection of specific chlamydial
agents or DNA sequences in clinical specimens, and 4) serological tests in which antibodies are
measured, preferably by demonstrating rising titers in paired acute and convalescent sera
(Andersen and Vanrompay 2003).
Direct visualization of Chlamydiae organisms in smears and paraffin-embedded tissue
sections can be performed by a number of techniques. Histochemical staining with Gimenez
(Gimenez 1967), modified Gimenez (Andersen 2004), Macchiavello’s (Macciavello 1937),
Stamp’s (Stamp, McEwen et al. 1950) and Giemsa (Campbell 1988) are techniques used to
demonstrate the characteristic chlamydial intracytoplasmatic inclusions present in impression
smears made from swabs, removed tissues, or yolk sac membranes after isolation. Sensitivity and
specificity of Giemsa (Munday, Johnson et al. 1980) and Gimenez staining has been studied
with varying results (Vanrompay, Ducatelle et al. 1992; Arizmendi and Grimes 1995). Cytologic
staining is inexpensive and easy to use, however, this technique has poor sensitivity and
specificity (Vanrompay 2000). Immunohistochemical staining is another method for detection of
chlamydiae in cytological and histological preparations and is more sensitivity and specific than
histochemical techniques (Elder and Brown 1999).
Isolation of C. psittaci organisms can be performed by inoculation onto cell culture
monolayers or into the yolk sac of embryonated chicken eggs (Vanrompay 2000). Combined
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samples from multiple sites (e.g., pharyngeal, cloacal) are recommended (Andersen 1996).
Aluminum shafted, Dacron-tipped swabs should be used to avoid false negatives from wooden
shafted and cotton-tipped swabs (Vanrompay 2000). Special chlamydial swabs are
commercially available, and a chlamydial transport medium formula has been published
(Vanrompay, Ducatelle et al. 1992). Cell cultures are the most convenient method for isolating
the avian strains of C. psittaci (Andersen and Vanrompay 2003). McCoy, HeLa, Vero, L929, and
buffalo green monkey cells are the most commonly used cell lines, although a number of other
cell cultures can be used (Andersen and Vanrompay 2003). Tissue cultures monolayers are fixed,
stained and examined for inclusions on day 2 and 3 post infection (Andersen and Vanrompay
2003). Embrionated chicken eggs of 6-7 days old and specific pathogen free certified are
inoculated with 0.2 -0.5ml/embryo into the yolk sac (Andersen 2004). The yolk sacs are
harvested from embryos that die from 3-10 days after inoculation. Yolk sac touch impressions
are prepared for histochemical and immunohistochemical stains (Andersen and Vanrompay
2003). Isolation is time-consuming, costly and is only preformed through specialized
laboratories. False negative results are possible, due to intermittent shedding and loss of
organism viability during transit time, treatment with antibiotics, transport medium toxicity or
thermal damage. False positive results are highly improbable when using cell culture techniques
(Fudge 1997).
Detection of antigens through direct immunofluorescence (IF), enzyme-linked
immunosorbent assay (ELISA) and immunochromatography have been used to diagnose C.
psittaci infections (Andersen and Vanrompay 2003). Most available test use a monoclonal
antibody (Mab) against the Chlamydiaceae-specific epitope LPS or against the species-specific
epitope on the MOMP , and were originally developed for the detection of C. trachomatis or C.
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pneumoniae in human isolates (Vanrompay 2000). Of the ELISA tests, IDEIA ( Dako
Diagnostics, UK), Chlamydiazyme (Abbot Laboratories, Abbott Park, IL) , CELISA (Cellabs),
SureCell (Eastman Kodak, NY-discontinued) have been evaluated for the detection of C. psittaci
in avian specimens (Biendl 1992; Haven, Mills et al. 1992; Kingston 1992; Ley, Flammer et al.
1993; Vanrompay, Van Nerom et al. 1993 ; Arizmendi and Grimes 1995). Most of these rapid
detection diagnostic tests are relatively low cost and easy to perform, do not require rigorous
maintenance of refrigeration for specimen shipment, and provide results much faster than culture
(Andersen and Vanrompay 2003). False positive results occur because the chlamydial LPS
shares some epitopes with other bacteria, and these epitopes can cross-react with assay reagents
(Vanrompay 2000; Andersen 2004). This problem has been reduced or eliminated in more
recently developed kits by careful selection of the Mabs (Andersen 2004). False negatives are
possible because of intermittent shedding of C. psittaci, inhibition of shedding by antibiotic
treatment and the intrinsic cut-off value of each test to detect small numbers of C. psittaci
organisms (Vanrompay 2000). Of the IF tests, Imagen (Dako Diagnostics, UK) and CEL-Vet
IF (Cell Labs, Brookvale, Australia), have also been evaluated for the detection of C. psittaci in
avian specimens (Vanrompay, Van Nerom et al. 1993 ). Immunfluorescence tests are performed
in specialized laboratories, and are suitable for small numbers of specimens. False positive
results can occure from nonspecific immunoglobulin binding, cross-reactivity of the Mab with
other organisms and technical microscopist inexperience. False negatives test results are possible
because of intermittent shedding of C. psittaci, inhibition of shedding by antibiotic treatment and
inexperience macroscopist (Vanrompay 2000). The immunochromatography test, CLEARVIEW
(Unipath , Ltd., Bedford, UK) has been evaluated for the detection of C. psittaci infection in
birds (Biendl 1992; Vanrompay, Van Nerom et al. 1993 ) with high percentage of false positive,

15

and false negative test result. The Speed Chlam (Bio-Vet Test, Diagnositc Veterinaire, Hyeres,
France), also an immunochromatography test, has not been evaluated in avian species. Overall,
of the different antigen detection tests evaluated in birds, the IMAGEN IF test seems to be the
most specific and sensitive. However, the current generation of rapid diagnostic tests are not
recommended to test for the presence of chlamydiae in the individual bird because they lack
both specificity and sensitivity (Vanrompay 2000; Andersen and Vanrompay 2003).
Detection of DNA sequences of the MOMP gene, pmp genes or the 16S-23S rRNA
through polymerase chain reaction (PCR) techniques are currently used in the diagnosis of C.
psittaci infections (Takashima, Imai et al. 1996; Hewinson, Griffiths et al. 1997; Messmer,
Skelton et al. 1997; Everett, Hornung et al. 1999; Laroucau, Souriau et al. 2001). Current PCR
techniques can detect DNA sequences of C. psittaci ante-mortem from swabs (e.g., conjuntival,
choanal, pharyngeal and cloacal), feces, biopsies and whole blood , and post-mortem from
tissues, cell cultures and embryonated eggs (Takashima, Imai et al. 1996; Messmer, Tully et al.
2000; Sareyyupoglu, Cantekin et al. 2007). PCR techniques for detection of C. psittaci DNA
have been compared in several studies to other diagnostic methods for avian chlamydiosis, and
currently is the most sensitive and specific diagnostic testing modality available (Domeika,
Ganusauskas et al. 1994; Trevejo, Chomel et al. 1999; Celebi and Ak 2006). Sensitivity and
specificity of simple PCR techniques have been improved with nested-PCR (Messmer, Tully et
al. 2000; Van Loock, Verminnen et al. 2005) and real-time PCR (Geens, Dewitte et al. 2005;
Heddema, Beld et al. 2006; Yang, Liu et al. 2006). Nested PCR allows detection and
differentiation of C. pneumoniae, C trachomatis and C. psittaci (Messmer, Tully et al. 2000).
Crontolled real-time PCR techniques allow detection and quantification of the DNA sequences
of the different C. psittaci genotypes in one test when the sample material is defined, without the
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need of RFLP analysis or sequencing (Geens, Dewitte et al. 2005). Current commercially
available PCR DNA based techniques for C. psittaci are not able to differentiate between
viable and non-viable organisms. PCR mRNA based techniques would allow to differentiate
between dead and alive or recently dead organisms at the time of sampling. PCR techniques
allow ease of sample collection, simple transport and storage and provide rapid results but are
performed only in specialized laboratories, and false positives occur from contamination during
sampling or processing (Vanrompay 2000).
Detection of antibodies is used in the diagnostic of avian chlamydiosis. Several studies
comparing different serologic antibody test in specific avian species have been published
(Piraino 1965; Grimes and Page 1978; Grimes 1986; Arizmendi and Grimes 1993; Grimes,
Phalen et al. 1993; Grimes, Tully et al. 1993; Salinas, Caro et al. 1993; Grimes and Arizmendi
1996; Grimes, Arizmendi et al. 1996; Tully, Shane et al. 1996). One of the most commonly used
tests has been the direct complement fixation (DCF). Direct complement fixation detects IgG
but not IgM (Grimes, Phalen et al. 1993). The concentration of IgG tends to increase late in the
course of infection and persist for months to years (Grimes 1993; Grimes, Phalen et al. 1993;
Grimes and Arizmendi 1996; Grimes, Arizmendi et al. 1996). DCF is readily available but the
test antigen is commercially unavailable (Vanrompay 2000). Direct complement fixation has
been evaluated in cockatiels experimentally inoculated with C. psittaci. In one study, DCF was
negative on day 8 in 13 cockatiels, had weak titers in 3 of 8 cockatiels on day 16, and were
positive 3 of 3 cockatiels tested on day 24 (Grimes, Tully et al. 1994). In other study, the DCF
was negative in days 4, 8, 16 post-inoculation, but attained 100% specificity and sensitivity on
the day 24 post-inoculation in the 10 cockatiels of the study group (Tully, Shane et al. 1996).
Titers ranging from 40 to 640 are frequently detected late in the course of infections (Grimes
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1996). The indirect or modified complement fixation test is more sensitive than the DCF.
(Grimes and Page 1978; Salinas, Caro et al. 1993). An improved latex agglutination (LA) was
used in conjunction with DCF for several years (Grimes, Phalen et al. 1993). The LA method
was not as sensitive as DCF for IgG detection (Grimes, Phalen et al. 1993; Grimes, Tully et al.
1994) and as the elementary body agglutination (EBA) for IgM detection (Grimes, Phalen et al.
1993; Grimes, Tully et al. 1994). The LA was phased out because of the difficulties in
producing satisfactory antigen (Grimes, Arizmendi et al. 1996). Elementary body agglutination
detects IgM but not IgG, and the concentration of IgM tend to increase early in the course of
infection and decrease later (Grimes 1996). Elementary body agglutination has been evaluated
in experimentally infected cockatiels and is considered a sensitive test (Grimes, Tully et al.
1994). Titers >10 in budgerigars, cockatiels and lovebirds and titers>20 in larger birds using
EBA are frequently detected in cases of recent infections (Grimes 1996). In pigeons, EBA was
not considered sensitive therefore CF is recommended (Phalen, Hofle et al. 1999). Indirect
immunofluorescence has been used in the detection of C. psittaci infection in birds (Salinas,
Caro et al. 1993; Cray and Bonda 2005). Indirect immunofluorescense antibody (Comparative
Pathology Lab, University of Miami School of Medicine) test is based on the detection of
antibodies against the reticulate body. Several novel protein antigens have been shown to be
expressed only in the inclusion and not in the EB stage (Rockey and Rosquist 1994). This
specific IFA detects primarily IgG (Cray, personal communication). Sensitivity and specificity
varies with the immunoreactivity of the polyclonal antibody to various avian species. Low titers
may occur because non-specific reactivity (Smith, Bradley et al. 2006). The sensitivity and
specificity of the test has been estimated to be 48.3% and 96.4 % from clinical cases in different
species (Cray, personal communication). In a study with cockatiels naturally infected with C.

18

psittaci and C. psittaci-free control birds, essentially no correlation was found between the CF
and EBA results and those of the IFA (Phalen 2001). In pigeons, a different immunoflurorescent
assay was found to have a sensitivity and specificity of 100% using an specific rabbit antipigeon IgG (Salinas, Caro et al. 1993). Enzyme-linked immunosorbent assays (ELISA) has been
used to detect C. psittaci infections in birds (Evans, Chalmers et al. 1983; Ruppanner, Behymer
et al. 1984; Fudge 1991; Thiele, Karo et al. 1992; Bendheim, Wodowski et al. 1993; Salinas,
Caro et al. 1993; Vanrompay, Lublin et al. 2000; Verminnen, Van Loock et al. 2006). Blockingantibody ELISA (AK-EIA, Röhm Pharma, Germany), a species independent commercially
available competitive test based on the detection of chlamydial lipopolysaccharide (LPS)specific antibodies, is highly sensitive but has low specificity (Fudge 1993; Tully, Shane et al.
1996; Verminnen, Van Loock et al. 2006) and is no longer in use (Phalen 2001). Solid- phase
ELISA (Immunocomb; Biolage Laboratories, Kibbuz Baled, Israel) was found to have a 100%
correlation with the CF in cockatiels naturally infected with C. psittaci and C. psittaci-free
control birds (Phalen 2001). Recombinant ELISA based on the detection of chlamydial MOMPspecific antibodies has been evaluated in several species of psittacines (Vanrompay, Lublin et al.
2000) and ducks (Verminnen, Van Loock et al. 2006). Recombinant ELISA does not
differentiate between IgG and IgM, however it is possible to identify the specific antibody type
by using an immunoglobulin isotype-specific monoclonal antibody against psittacine IgG and
IgM instead of the cross-reactive chicken/turkey IgG conjugate (Vanrompay, Lublin et al. 2000).
The reactivity of the chicken/turkey IgG conjugate with several species of psittacines was
determined (Vanrompay, Lublin et al. 2000). Cockatiel IgG does not cross react with antichicken IgG (Baghian, Reyes et al. 1999), and is not known how the recombinant ELISA would
perform in cockatiels. All the antibody detection test mentioned, other than the recombinant
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ELISA, are based on the use of whole body chlamydial organisms, LPS, or chlamydial outer
membrane fractions of LPS and lipoglycoporteins nature (Vanrompay 2000). Using these
sources of antigen, false positive results due to the presence of antibodies cross-reactive with
other Gram negative bacteria such as Escherichia coli, Salmonella typhimurium, Neisseria
gonorrhoeae and Coxiella burnetii to the chlamydial LPS or chlamydial hsp60 cannot be ruled
out (Nurminen, Wahlstrom et al. 1984; Yuan, Lyng et al. 1992; Haralambieva, Iankov et al.
2001)
There are three case definitions as established by the National Association of State Health
Veterinarians (NASPHV) and the Centers for Disease Control and Prevention (CDC) in
“Compendium of measures to control C. psittaci infection among humans and pet birds,
2006”(Smith, Bradley et al. 2006).
1) Confirmed case – is defined on the basis of at least one of the following laboratory results: a)
isolation of C. psittaci from a clinical specimen, b) identification of chlamydial antigen by
immunofluorescence (fluorescent antibody [FA]) of the bird’s tissues, c) a greater than fourfold
change in serologic titer in two specimens from the bird obtained at least 2 weeks apart and
assayed simultaneously at the same laboratory, or d) identification of C. psittaci within
macrophages in smears stained with Gimenez or Macchiavello stain or sections of the bird’s
tissues.
2) Probable case – is defined as compatible illness and at least one of the following laboratory
results: a) a single high serologic titer in one or more specimens obtained after the onset of signs
or b) the presence of C. psittaci antigen (identified by ELISA, PCR, or FA) in feces, a cloacal
swab or respiratory or ocular exudates.
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3) Suspected case – is defined as a) compatible illness that is epidemiologically linked to another
case in a human or bird but that is not laboratory confirmed, b) a subclinical infection with a
single high serologic titer or detection of chlamydial antigen, c) compatible illness with positive
results from a nonstandardized test or a new investigational test, or d) compatible illness that is
responsive to appropriate therapy.
These case definitions should help the clinician interpret the diagnostic test results as they
relate to a patient that may have signs consistent with avian chlamydiosis or subclinical
cases. To aid in diagnosis a complete patient history should be taken from the owner, an external
physical examination performed and basic diagnostic tests submitted including a complete blood
count, plasma chemistry panel and radiographs. If avian chlamydiosis is suspected, treatment
should be initiated until the diagnosis is confirmed, a clinical response is achieved or another
diagnosis determined.
2.1.6 Lesions
Descriptions of gross and histophatologic lesions caused by generalized C. psittaci
infection have been reported in psittacines (Rivers, Berry et al. 1931; Graham 1989; Suwa,
Touchi et al. 1990; Graham 1993), chickens (Storz, Call et al. 1963; Takahashi, Takashima et al.
1988; Suwa, Ando et al. 1990), rheas (Camus, Cho et al. 1994), houbara bustard (Greth, Andral
et al. 1993), turkeys (Beasley, David et al. 1959; Gale, Sanger et al. 1960; Beasley, Davis et al.
1961; Vanrompay, Ducatelle et al. 1994), and in pigeons and ducks (Andersen and Vanrompay
2003). Many factors such as species, age, immune status, route of exposure, and the C. psittaci
strains contribute to the wide range of pathological findings described in the literature (van
Buuren, Dorrestein et al. 1994).
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The macroscopic lesions can vary as widely as the clinical disease (Gerlach 1994). Acute
lesions are characterized by hepatomegaly, fibrinous peritonitis, air sacculitis, perihepatitis,
pericarditis, bronchopneumonia, enteritis and nephrosis. Miliary necrosis of parenchymal organs
is common, probably due to the effects of chlamydial toxins. Splenomegaly is frequently
discussed as a common finding in chlamydiosis. However, fibrinous air sacculitis is more
indicative of chlamydiosis in Psittaciformes. Splenomegaly may not occur with chlamydiosis at
all. In sexually active males, chlamydial-induced orchitis or epididymitis results in permanent
infertility. Oophoritis is rare (Gerlach 1994). Subacute to chronic lesions are characterized by
anemia caused by a panmyelopathy in the bone marrow and tissue deficiencies of heterophils and
macrophages(Gerlach 1994). Chronic cases are characterized by proliferation of connective
tissue (up to cirrhosis) in the liver and kidney and pancreatic necrosis has been described
(Gerlach 1994).
The liver from a bird that has been infected with C. psittaci may be of normal size and
color, or may be enlarged to a lesser or greater degree, usually with some rounding of the edges.
The color of the affected liver may be in normal range- a uniform reddish brown, diffusely
yellow-tan to dark olive brown, or light yellow - or orange-tan depending on the relative degree
of congestion, bile stasis, lipidosis and hepatocelular degeneration of necrosis that have occurred
and chromatically combined. In some instances, the lobular architecture is accentuated by a
zonal distribution of congestion within the liver lobule. In some cases there may be grossly
discernable punctate to large, irregularly shped foci of coagulation necrosis that are usually light
yellow-tan and contrast with different or darker background (Graham 1993).
The spleen of a bird that has died of C. psittaci infection may be within normal limits of
size, but is often enlarged to a moderate to pronounced degree. The enlarged spleen may be firm
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with a tense capsule or somewhat soft flaccid; the latter is commonly the result of post-mortem
autolysis if necropsy has been delayed. The dark red color to reddish purple characterizes the
congested spleen, while splenomegaly predominantly caused by the increased cellularity of
histiocytosis and plasmacytosis may be grey-tan to light yellowish-tan (Graham 1993).
The air sac surfaces may accumulate fibrinous exudates. The interclavicular, cranial, and
caudal thoracic, and abdominal air sacs are all potential sites of fibrinous inflammation. The
mesothelium-covered surfaces of the pericardial and coelomic cavities and the serosal surfaces of
the viscera are also at risk of fibrinous inflammation (Graham 1993).
The microscopic findings are mostly nonspecific except for the presence of LevinthalCole-Lillie (LCL) bodies, which are pathognomonic. Levinthal-Cole-Lillie bodies can occur in
many organs but are especially common in serosal membranes (Gerlach 1994). The single most
consistent histopathological feature of lesions associated with infections caused by C. psittaci in
birds is hystiocytosis- increased numbers and size of cells of the hystiocyte/macrophage systemwhether in the interstices of parenchymatous organs or as the predominant cellular component of
fibrinous exudates on air sac and serosal surfaces (Graham 1993). Typical of more acute
disease is the intrasinusoidal proliferation of Kupffer’s star cells (pearl string-like appearance) in
the liver. Proliferation of monocytes and activation of the reticuloendothelial system may occur
in parenchymal organs, particularly the spleen, liver and kidney (Gerlach 1994). Epithelioid cell
granulomas in the liver and pneumonia with proliferations of epithelial cells in the air capillaries
are common with chronic cases. Swollen epithelial cells may be vacuolated, and migration of
lymphocytes into the damaged tissue can be seen. Central nervous system (CNS) lesions consist
of nonpurulent meningitis. Secondary bacterial, fungal or viral infections may alter lesions and
mask changes consistent with C. psittaci infection (Graham 1989).
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In the liver, intrasinusoidal histiocyte (Kupffer cell) hyperplasia, often accompanied by
local or diffuse mononuclear cell infiltration, is the common manifestation of subacute to chronic
chlamydiosis of mild to moderate degrees of severity. Slight to marked intrahepatocellular bile
stasis and accumulation of iron pigment are frequent sequelae of hepatitis. Multiple foci of
coagulation necrosis of hepatic parenchyma has been described as prominent lesion resulting
from experimentally induced avian chlamydiosis in parrots and may be the only lesion observed
grossly or histologically in the acute fatal diseases. Moderate to marked bile duct hyperplasia in
recurrent, subacute episodes of avian chlamydiosis may be present over a period of many
months or even years (Graham 1989).
In the spleen, hyperplasia of histiocytes in the perivascular sheaths of the arterioles, with
consequent thickening of the sheaths, is common in the spleen of parrots with clinical signs of
chlamydial infections. The degree of splenomegaly evident is generally quantitatively
proportional to the amount of histiocytosis present. Depletion of lymphocytes from the white
pulp is common; it may be a relative decrease, but in many cases, the lymphocyte paucity is
absolute and accompanied by absolute plasmacytosis (Graham 1989).
In the airsacs, acute cases are characterized by fibrinous exudates that contain few
heterophils and macrophages that may harbor C. psittaci organisms. In subacute airsaculitis, the
exudates typically contain many reactive, vacuolated macrophages which may again harbor C.
psittaci organisms; a few heterophils may also be found. Chronic chlamydial airsacculitis may be
classified as diffuse granulomatous or pyogranulomatous inflammation with stromal
histiocytosis and the presence of macrophages in exudates remnants. Stromal fibrosis and
neovascularization may also be observed in those regions of the air sac near its reflection from
the body wall, lung surface in chronic avian chlamydiosis cases (Graham 1989).
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In conclusion, the gross and histophatological lesions observed in cases of avian
chlamydiosis are typically those that may be expected to occur in response to a variety of
generalized bacterial infections (Graham 1993). Definitive diagnosis of chlamydiosis, depends
on the demonstration of chlamydial organisms or chlamydial antigens in typical lesions by
chromatic stains or specific staining with labelled antibodies (Graham 1993).
2.1.7 Treatment
In vitro activity of different antibiotics against C. psittaci has been studied. Lindenstruth
reported a minimum inhibitory concentration (MIC) of enrofloxacin for C. psittaci strains of
0.125 µg/ml, and a minimum bactericidal concentration (MBC) of 50-75 ug/ml. In the same
study, Lindenstruth reported that concentrations of 0.5-1 ug/ml caused irreversible damage to the
majority of C. psittaci particles (Lindenstruth 1992). Kimura et al. published in vitro and in vivo
antichlamydial activities of sparfloxacin, tosufloxacin, and OPC-17116, newly developed
quinolone antimicrobial agents (Kimura, Kishimoto et al. 1993). Miyashita compared in vitro
MIC of different fluoroquinolones, doxycycline, azytrhomycin and clarythromycin against two
different strains of C. psittaci, finding the MIC ranged from 0.063 to 2 µg/ml in the
fluoroquinolones, while those of doxycycline, azythromicin and the clarithromycin were 0.031
to 0.063, 0.125 and 0.016 µg/ml, respectively (Miyashita, Niki et al. 1997). Butaye reported the
in vitro activities of doxycycline and enrofloxacin against European C. psittaci strains from
turkeys. Both doxycycline and enrofloxacin showed strong in vitro antimicrobial activities
against C. psittaci strains isolated from turkeys in Europe. For doxycycline the MIC ranged from
0.05 to 0.2 µg/ml, with an average of 0.1 µg/ml. For enrofloxacin the MIC was 0.25 µg/ml.
Acquired resistance was not detected in the strains tested against doxycycline and enrofloxacin
(Butaye, Ducatelle et al. 1997). Donati et al., studied first in vitro activity of moxifloxacin,
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minocycline, azithromycin and garenoxacin against Chlamydia spp., and compared to the
activity against C. psittaci organisms of levofloxacin, ciprofloxacin, doxycycline, erythromycin
and roxithromycin. From these data, the studies concluded that quinolones kill chlamydial
strains at concentrations equivalent to their MICs, while antibiotics like azithromycin would
require two to four times the MIC (Donati, Rodriguez Fermepin et al. 1999; Donati, Pollini et al.
2002). Failing et al., 2006 determined the inhibitory concentration 50% (IC50) of four selected
drugs (chlortetracycline, doxycycline, enrofloxacin and difloxacin) that reduce in vitro the
multiplication of C. psittaci. Complete prevention of inclusion formation was already seen for
enrofloxacin at a concentration of 1.0 µg/ml in 12 out of 20 and for difloxacin in 5 out of 20
isolates whereas more than 10 µg/mI chlortetracycline is needed in 15 out of 20 isolates and for
doxycycline 9 out of 20 isolates yielded inclusions at 10 microg/ml (Failing, Theis et al. 2006).
No significant difference in antimicrobial drug sensitivity were present among strains of C.
psittaci in the above in vitro studies. Other in vitro studies in other members of the It has been e
clearly demonstrated that the susceptibility of Chlamydiaceae to antibiotics was dependent on
host cells, finding infections withing monocytes and lymphocytes to be refractory to treatment
(Gieffers, Fullgraf et al. 2001; Yamaguchi, Friedman et al. 2003). Antimicrobial resistance to a
strain of C. psittaci recovered from ducks has also been reported (Johnson and al 1983).
Tetracyclines like doxycycline, oxytetracycline and chlortetracycline are considered
bacteriostatic antimicrobial agents. Tetracyclines alter the replication of Chlamydiacea by
inhibiting the synthesis of enzymes, the growth and fision of the reticulate bodies, and possibly
the reorganization of the elementary bodies (Gerlach 1994). Antimicrobial-induced damage that
occurs may be temporary, with the organism resuming normal replication within 5.5 days of
ceasing therapy (Gerlach 1994). Tetracyclines are effective only against actively metabolizing
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organisms (e.g., during growth of fision) (Flammer 1989; Gerlach 1994). This drug is not
effective in treating persistently infected birds in which the organism is located inertly in
macrophages without activity (Gerlach 1994). Prolonged treatment periods of 30 to 45 days are
thought necessary to eliminate the infection (Flammer 1989; Dorrestein 1993), but the
hypothesis that the organism is eliminated by the natural replacement of infected host cells if
treatment is continued for such prolonged periods has not been confirmed using currently
available diagnostic techniques (Gerlach 1994). The recommended treatment period for avian
chlamydiosis has historically been 45 days (Smith, Bradley et al. 2006).
Doxycycline is presently the drug of choice for treating avian chlamydiosis in pet birds
(Smith, Bradley et al. 2006). Doxycycline is a semisynthetic tetracycline derivate with numerous
pharmacologic advantages compare with other tetracyclines (Flammer 1997). It has a higher oral
bioavailability and a longer elimination half-life than other tetracyclines, which results in lower
doses (improving palatability) and less frequent administration (improving ease of treatment)
(Flammer 1997). The goal of the treatment is to maintain a concentration >1 µg/ml for the
duration of the treatment period. This concentration is thought to inhibit C. psittaci replication
(Prus, Clubb et al. 1992; Flammer 1997; Powers, Flammer et al. 2000; Flammer, Whitt-Smith et
al. 2001; Flammer, Trogdon et al. 2003; Flammer and Papich 2005; Padilla, Flammer et al.
2005). Pharmacokinetic studies have been done in pigeons (Columbia livia) (Dorrestein, Bruijne
et al. 1991), chickens (Gallus domesticus)(Anadon, Martinez-Larranaga et al. 1991; Laczay,
Semjen et al. 2001), Houbara bustard (Chlamydotis undulata) (Greth, Gerlach et al. 1993),
turkeys (Meleagris gallopava) (Santos, Vermeersch et al. 1996) and ostriches (Struthio
camelus). Several studies evaluating plasma levels after parenteral and oral administration have
also been performed. Teichmann evaluated the blood levels in cockatiels after parenteral
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administration (Teichmann and Gerlach 1976). Flammer reported plasmatic levels in orangewinged amazon (Amazon amazonica), Goffin’s cockatoo (Cacatua goffini) and African grey
parrots (Psittactus erithacus timneh) after parenteral administration of particular formulation of
pharmacist-compounded doxycycline (Flammer and Papich 2005). A specific doxycycline
formulation, Vibramycin, that is appropriate for intramuscular (IM) administration is available
in Europe and can be imported into the US. The injectable hyclate formulation labeled for IV
use in humans can be administered to birds intravenously, but is not suitable for intramuscular
use because of severe tissue necrosis that will occur at the site of injection (Smith, Bradley et al.
2006). Flammer, from unpublished studies, suggested that once-daily oral administration of
doxycycline in several psittacine species could maintain appropriate plasma levels. The high
doses needed for this treatment regimen in some species could cause regurgitation in some
individuals (specially macaws). The elimination half life varied with the species, and different
dosages are suggested (Flammer 1997). Treatment regimens using doxycycline in medicated
food and water have been reported. Prud reported doxycycline plasma concentrations in macaws
fed a medicated corn diet (Prus, Clubb et al. 1992). Santos studied the administration of
doxycycline hydrochloride via drinking water to turkeys under laboratory and field conditions
(Santos, Vermeersch et al. 1997). Powers reported treatment regimens in water and food in
cockatiels, and compared the plasmatic levels to an injectable regimen (Nymphicus hollandicus)
(Powers, Flammer et al. 2000). Flammer reported a treatment regimen in water in Goffin’s
cockatoos (Cacatua goffini) and African grey parrots (Psittacus erithacus timneh) (Flammer,
Whitt-Smith et al. 2001) and a feed regimen in water and seed in budgerigars (Melopsittacus
undulatus) (Flammer, Trogdon et al. 2003). Padilla studied a treatment regimen in water in
exotic doves (Padilla, Flammer et al. 2005).
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Oxytetracycline parenteral studies were completed by Flammer in Goffin’s cockatoos to
provide an alternative to the injectable doxycycline not readily available in the US. Plasma
concentrations (>1ug/ml) were maintained when long-acting oxytetracycline was administered
subcutaneously at dosages of 75 to 100 mg every 3 days (Flammer, Aucoin et al. 1990). Similar
results were found in four other avian species in unpublished studies, including African grey
parrots, blue and gold macaws, orange-winged Amazon parrots, and pigeons. (Flammer 1997).
In these studies, IM administration was found to cause severe tissue irritation and is not
recommended and repeated subcutaneous administration caused irritation. After stabilization
with oxytetracycline treatment, the birds should receive another form of treatment to reduce
irritation that is caused by repeated oxytetracycline injection (Smith, Bradley et al. 2006).
Chlortetracycline (CTC) medicated feed has been historically the recommended method
of treatment in poultry (Vanrompay, Ducatelle et al. 1995; Andersen and Vanrompay 2003). The
goal of the treatment is to maintain a concentration >1 µg/ml for the duration of the treatment
period. This standard is based on limited experimental studies correlating treatment efficacy with
maintenance of CTC blood concentrations above 1µg/ml for 30 to 45 days (Arnstein, Eddie et al.
1968; Arnstein, Buchanan et al. 1969; Wachendorfer 1973). In some situations blood
concentrations above 1 µg/ml did not eliminate the infection (Gerlach 1994), while in others
blood levels below 1 µg/ml were able to eliminate infection (Gylsdorff 1984). Oxytetracycline
has a short elimination life administered oral or parenteral (3-4 hours), and required
administration via drinking water or food. Several reports have been published regarding this
route of administration in psittacines (Pollard 1958; Doherty, Carley et al. 1961; Arnstein, Eddie
et al. 1968; Arnstein, Buchanan et al. 1969; Wachendorfer, Luthgen et al. 1973; Wachendorfer,
Luthgen et al. 1973; Hirchert 1974; Cooper 1980; Luthgen, Fuller-Baartz et al. 1981; Landgraf,
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Ross et al. 1982; Flammer, Cassidy et al. 1989), pigeons (Wachendorfer and Luthgen 1974),
turkeys (Andersen and Vanrompay 2003) and ducks (Arzey, Arzey et al. 1990). The interactions
between palatability, energy content, and potential binding agents (e.g., calcium and certain
proteins) are complex, thus requiring careful planning (Flammer 1997).
Despite promising in vitro sensitivity results to C. psittaci, fluoroquinolones like
enrofloxacin and ciprofloxacin, alleviate clinical signs but seldom clears birds of C. psittaci
infection (Flammer 1997). The goal of the treatment is to maintain a concentration >0.5 µg/ml
for the duration of the treatment period. Several reports have been published regarding the use
of enrofloxacin as a treatment against C. psittaci infections (Jung 1992; Lindenstruth and Frost
1993).
Macrolides, like azytromycin and clarithromycin, are drugs that theorically could be used
for the treatment of avian chlamydiosis. Diaz-Figueroa validated the use of three week course of
azithromycin for C. psittaci infection in cockatiels (Diaz-Figueroa, Tully Jr. et al. 2006). These
results, although promising, require further investigations.
2.1.8 Prevention and Control Methods (Smith, Bradley et al. 2006)
To prevent transmission of C psittaci to humans and birds, specific control measures are
recommended including to protect persons at risk, maintain accurate records of all bird-related
transactions for at least one, avoid purchasing or selling birds that have signs consistent with
avian chlamydiosis, isolate newly acquired/ ill/ exposed birds, test birds before they are to be
boarded or sold on consignment, screen groups of birds with frequent public, practice preventive
husbandry, control the spread of infection, use disinfection measures (effective disinfectants
include 1:1,000 dilution of quaternary ammonium compounds (eg, Roccal or Zephiran), 1%
Lysol or 1:32 dilution of household bleach.)
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Birds with confirmed or probable avian chlamydiosis should be isolated, treated and
monitored daily, protecting birds from undue stress/ poor husbandry/ malnutrition and
removing oyster shell, mineral blocks, and cuttlebone during treatment since calcium may
interfere with absorption of tetracyclines.
Humans exposed to birds with avian chlamydiosis should seek medical attention if they
develop influenza-like symptoms or other respiratory tract illnesses. Birds that are suspected
sources of human infection should be referred to veterinarians for evaluation and treatment.
Local health authorities should report suspected cases to their state health department.
Public health and animal health authorities at the local or state level may need to conduct
epidemiologic investigations to control the transmission of C. psittaci to humans and birds.
The appropriate animal or public health authorities may issue an official quarantine for all
affected and exposed birds on premises where C. psittaci infection has been identified.
Illegally imported birds are a rare but potential source of new C. psittaci infection to
domestic flocks. The Veterinary Services of the Animal and Plant Health Inspection Service,
USDA, still regulates the legal importation of companion birds to ensure that exotic poultry
diseases are not introduced into the United States. These regulations are set forth in the Code of
Federal Regulations, Title 9, Chapter 1.
2.1.9 Public Health Since
C. psittaci can cause disease in humans, it becomes a public health issue to avoid disease
and deaths in the general public and workers at risk. Some examples: a case of psittacosis linked
to a bird distributor in Mississippi, Massachusetts and Tennessee (CDC 1992), ornithosis in
workers at a duck farm and processing plant (Hinton DG 1993), an outbreak of pisttacosis linked
to a veterinary hospital (Heddema, van Hannen et al. 2006), and outbreak of psittacosis in
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customs officers (De Schrijver 1995), and a psittacosis outbreak linked to free-ranging birds
with or without direct contact (Williams, Tallis et al. 1998; Telfer BL, Moberley SA et al. 2005;
Herrmann, Persson et al. 2006; Matsui, Nakashima et al. 2007).
From 1988 through 2003, a total of 935 human cases of psittacosis attributed to C.
psittaci were reported to the US Centers for Disease Control and Prevention; most were related
to contact with Psittaciformes. However, at the time of this report there was limited diagnostic
differentiation between humans infections associated with C. psittaci and those associated with
C. pneumonia. Currently, approximately 100 psittacosis cases are reported annually in the United
States, and one person may die of this disease each year (Vanrompay D, Harkinezhad T et al.
2007).
Human infections are characterized by flu-like clinical signs including a high fever,
severe headaches, chills, shortness of breath and general debilitation. If untreated, atypical
pneumonia or CNS signs, mainly caused by meningitis, can develop, in addition to liver and
kidney lesions due to the presence of toxicity. In rare cases, neuritis with severe pain is
described. Chronic manifestations include arteritis, cardiovascular insufficiencies and
thrombophlebitis that result in an including insufficiency of the venal valves.
2.2 Avian Chlamydiosis Vaccinology
2.2.1 General Principles
The goal of any vaccine is to stimulate immunity to a specific pathogenic organism via
controlled antigen exposure of the host. While this goal usually is achieved to high efficacy, no
vaccine protects all vaccinates from infection. However , the few animals that are vaccinated and
fail to develop immunity are still afforded some protection by being surrounded by a population
of animals that have been successfully vaccinated (Ritchie BW 1999 ).
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The general principles of the immune system apply whether one is discussing mammals
or birds. They share a common purpose: the elimination of foreign antigens from the body. The
innate immune response serves as first line of defense upon exposure to such a substances, and
consists of the natural defenses such as the skin and mucous membranes as well as the
phagocytic cells of the body, including macrophages and neutrophils. It´s a non-specific response
directed towards any pathogen that the body may encounter. Another principal characteristic is
that there is a lack of memory or long-term response associated with this part of the immune
system (Janeway CA 1999; Janeway CA 1999). The adaptative immune response responds to
antigens that have eluded the innate response. This response becomes effective after several
days, due to the time it takes to mount a response by the T and B cells as they mature and
proliferate. Once initiated the adaptative response results in development of a host of B and T
cells that exhibit specificity for a particular antigen, allowing the body to mount a directed
immune response. This adaptive immunity is the type of immunity induced upon vaccination
(Janeway CA 1999; Janeway CA 1999).
The adaptative immune response has two important parts termed humoral and cellular
immunity. Humoral immunity is characterized by antibody production resulting from the
maturation of B cells. Plasma cells are terminally differentiated B cells and they produce
antibodies that are specific for a particular antigen. A population of “memory” B cells also
develops for the purpose of generating a secondary response if the body is exposed to that
particular antigen again at a later time (Janeway CA 1999). Cellular immune response consists of
populations of T lymphocytes that serve various functions in creating antigen-specific
immunity. T-helper cells, or CD4+ lymphocytes, serve to produce various interleukins,
interferon gamma, and to stimulate cytotoxic T lymphocytes and suppressor T lymphocytes ,
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activate macrophages, and stimulate further helper T cell activation. These cells also play a role
in augmenting humoral immunity by stimulating proliferation and differentiation of B cells. The
CD4+ T lymphocytes contain antigen receptors that recognize the peptide displayed by major
histocompatibility complex (MCH) II molecules. Cytotoxic T cells, or CD8+ T lymphocytes,
are directly cytotoxic to cells containing internalized antigen, which are most commonly virallyinfected cells. CD8+ T lymphocytes recognize and process antigen displayed in the context of
MCH I molecules. During immune stimulation, a population of memory T cells are also
developed that will respond to challenge by the same antigen in the future (Janeway CA 1999).
However, there are numerous examples of dissimilarity between mammals and birds with
regard to their immune system, such as the ontogeny of T and B cells, peripheral lymphoid
organs, and some differences in the white blood cells at the cellular and subcellular level, in the
major histocompatibility complex (MCH) and in the immunoglobulines. Our understanding of
avian immunity is mainly restricted to that of the chicken (Gallus domesticus) since most of the
avian immunity literature is regarding this specie. Recognized differences do exist between
gallinaceous birds and psittacines with regard to their immne system. For example, monoclonal
antibodies specific for chicken serum IgY do not specifically cross-react with the psittacine bird
sera. This indicates significant structural variation between the 2 IgY (Phillips KM 2003).
There are different types of vaccines:
- Killed
- Live attenuated
- Subunits
- synthetic peptides
- recombinant DNA
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Inactivated of killed vaccines, consist of treated organisms that are unable to replicate;
however, they do not elicit protein production in the cytosol and hence viral antigens can not be
presented by MCH class I molecules, thus cytotoxic CD8 T cells are not generated. Live
attenuated vaccines are more potent educes of a greater number of relevant effector mechanisms,
including cytotoxic CD8 T cells. Nevertheless, these vaccines sometimes have residual
pathogenicity (Ferreira TB 2005).
Synthetic peptides should be as effective as live whole organisms and are inherently
safer than vaccines based on whole organisms, but they are not strongly immunogenic, being
particularly difficult to obtain MCH class I specific responses (Ferreira TB 2005).
DNA vaccines cause in the direct transfer of a bacterial plasmid into the animal cells.
The gene encoding an immunogenic protein is first inserted in a eukaryotic expression plasmid.
In essence, the vector contains a prokaryotic replication origin that allows production of the
plasmid in the bacteria, an antibiotic resistance gene for selective growing, a strong viral
promoter and a polyadenylation/transcriptional termination sequence for the expression of the
cloned gene in mammalian cells. The vaccinal plasmid is then delivered into the host and is
taken up by host cells where the encoded protein is synthesized. This protein recognized as a
foreign antigen becomes the target of the host immune system; the antigenic protein is processed
and presented to the immune system where it induces a broad range of immune responses. The
DNA vaccination can generate a specific humoral immunity, mediated by CD4+ T lymphocytes
and caracterized by the production of antigen specific antibodies, and a cellular response,
including the activation of CD8+ lymphocytes, essential for protection against intracellular
pathogens.
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Virus vectors, like adenovirus, are highly efficient at transferring genetic material in a
broad spectrum of cell types and species. Adenoviruses can infect a wide variety of dividing and
non-dividing cells, causing ubiquitous infections without significant or severe clinical signs. The
genome of these viruses is well characterized, and the techniques for the construction of
recombinant adenovirus are well establish, being able to accommodate up to 36 kb of foreign
genetic material. Adenoviruses have the ability to deliver antigen into the lymphoid tissues,
producing a sustained, high-level antigen specific cellular response that explains the strong
immunogenicity of these vectors (Ferreira TB 2005). In the same way, adenovirus are also used
for delivering vaccines to mucosal surfaces (Babiuk and Tikoo 2000).
Immunostimulants, like chitosan, are used to increase the immune response to the
vaccine. Chitosan is a cationic polysaccharide obtained from the alkaline deacetylation of chitin,
the principal component of exoskeletons of crustaceans and insects as well as of cell walls of
some bacteria and fungi (Illum, Jabbal-Gill et al. 2001). It exhibits a variety of physicochemical
and biological properties that makes it very attractive substance for systemic and local delivery
of vaccines. In addition to its lack of toxicity and allergenicity, it is biocompatible,
biodegradable and bioactive. Chitosan improves delivery of DNA through mucoadhesion,
enhancement of mucosal epithelial permeability, the formation of nanoparticles that protect and
control the release of DNA and enhancement of local and systemic immune responses (Senel S
2004). This makes chitosan very suitable for nasal vaccine delivery (van der Lubben, Verhoef et
al. 2001) (Vanrompay, Cox et al. 2001)
From a preventive medicine point of view a vaccine would be an effective method to
combat the disease, although in practice it is not been easy to engineer effective vaccines
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against C. psittaci. There are several biologic features of C. psittaci that makes it difficult
(Gerlach 1994):
1) The agent is capable of inhibiting host defense mechanisms. This allow the agent to survive in
propagating cells and possibly cause chronic infections that probably cannot be treated
successfully inside the host cell.
2) The inhibition of phagolysosomes in macrophages compromises immunological processed,
leaving survivors that demonstrate genus specific antibodies that are not protective (Tully 2005).
3) The high variability of the avian chlamydial strains is determined by the MOMP, which
represents the receptor capacities, the toxic properties, and, therefore, host susceptibility and
virulence.
4)The persistence of C. psittaci in macrophages of one avian species selects strains of low
virulence for the species concerned, but may be fully virulent when infection other species
(Gerlach 1994).
Serum and mucosal antibody levels have not been correlated to a higher protection
level in previous studies with turkeys (Vanrompay, Cox et al. 1999; Verminnen, Van Loock et
al. 2005), and cell-mediated immunity is thought to play a major role in the immunological
protection of the host. In the murine model for C. trachomatis , CD4+ T helper type 1 (Th1),
CD8+ T cells, mononuclear phagocytes and cytokines secreted by these cells are considered
potential effectors of anti-chlamydial immunity (Johansson, Schon et al. 1997; Williams, Grubs
et al. 1997). In the guinea pig (Cavia caviae) infection model, both humoral and cell mediated
immunity seem to be important to clearing the infection and for resistance against reinfection
(Rank, Soderberg et al. 1989).
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2.2.2 Vaccine Trials
Formalin-inactivated concentrated suspensions of chlamydiae injected repeteadly by
intraperitoneal (IP) route into mice protected them against challenge by the same route with
homologous or heterologous strains (Wagner J 1946).
Other investigators have had similar results in immunizing mice against challenge with
chamydial agents, but the same success has not been achieved with birds. Formolized bacterins
mixed with adjuvants have not provided decisive immunity to chlamydiosis in domestic fowl or
psittacines.
Rice birds and parakeets inoculated with formolized chlamydiae were immune to small
challenge doses (100MLD 50) but not larger ones (Meyer, Eddie et al. 1942). Pigeons vaccinated
with similar preparations and then exposed 4 months later were as susceptible to reinfection by
natural means as nonvaccinated controls (Hughes DL 1947). Turkeys inoculated with
intramuscular injections (IM) three times one month apart with formolized chlamydiae mixed
with homogenized oil adjuvants (Bayol-F, Arlacel A) resulted in marginal protection in terms of
mortality and lesion reduction. More important, triple vaccination was ineffective in preventing
chronic infection and the carrier stage. In the vaccinated group, gross lesions were present in
33% of them and the organisms were recovered in 14%, versus 50% and 47% respectively in the
control group (Meyer KF 1962). Parakeets inoculated with with formolized chlamydiae showed
a decreased incidence of lesions of 5% in one experiment and 60% in another (Arnstein 1967).
Parakeets inoculated with live chlamydiae, and then administered chlortetracycline as
treatment achieved significant protection against challenge infection. Only 3% of the treated
birds had lesions after challenge infection, whereas 73% of nontreated birds had lesions after
challenge (Meyer KF 1962).
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Turkeys inoculated with Chlamydial bacterins twice at 8 week interval, protecting 100%
of the vaccinated birds against mortality and 90% to lesions after challenge infection. The
bacterin inoculation did not stimulate antibody response, but enhanced cell mediated immunity.
If the 2 inoculations were given 2, 4 or 6 weeks apart, protection percentages were much lower
than that produced by the 8 week inoculation interval. Also, a single intratracheal inoculation of
bacterin or 2 IM inoculations of bacterin resulted in lower protection percentages. Disease
resistance was measured after vaccination and prior to challenge by an in vitro blood test using
peripheral lymphocytes from the birds. Resistance to infection was correlated directly with
mytogenic response of lymphocytes cultured in the presence of suspensions of purified
chlamydiae. Surgical bursectomy or thymectomy at 1 day posthatch confirmed the role of cell
mediated mechanisms in chlamydial immunity. Bursectomy did not impair ability of turkeys to
develop solid bacterin-induced immunity to challenge infection, whereas thymectomy prevented
development in most of the birds. Nonbacterin inoculated controls, whether bursectomized or
not, were completely susceptible to challenge infection. The use of this vaccine was considered
limited in turkeys, due to the cost of application, however other domestic poultry (e.g., pigeons
and doves) and pet birds (e.g., psittacines) could have benefit from bacterin immunization. The
conclusions of the study indicated that application of potent immunizing preparations, proper
timing, and route of administration should provide the basis for effective immunizations of birds
(Page 1978).
Cockatiels inoculated IM with genetically engineered C. psittaci MOMP vaccine showed
humoral response to the C. psittaci antigen but in low titers. Five groups of 5 cockatiels were
used. Group 1 received formalin inactivated elementary bodies, group 2 received the MOMP
plasmid subunit vaccine, group 3 received the MOMP gene, group 4 received the MOMP subunit
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and gene combination vaccine and the group 5 served as a control. Birds received two booster
shots in 4 week intervals. Three weeks following the last booster shot the birds were bled for
evaluation of antibody response and challenged with 105 infectious C. psittaci elementary
bodies, via nasal an ocular mucosa. Clinical signs were monitored after inoculation and the
animals evaluated serologically for active infection. On day 24 post challenge, the birds were
euthanized and examined for pathological evidence of C. psittaci infection. No C. psittaci
organisms were isolated from birds surviving the 24 day inoculation study. Four birds died
during the study, from which C. psittaci organisms were cultured (Tully TN 1997). This was the
first study using recombinant MOMP DNA.
Turkeys inoculated by gene gun and combining IM and intranasal (IN) routes with
plasmid MOMP DNA twice 3 weeks apart, showed raising humoral (Ig G) and cellular
responses. Severe clinical signs and lesions were only observed in the non-vaccinated challenged
control group, but all vaccinated turkeys showed lesions in the air sacs. All turkeys of the nonvaccinated challenged control group had a positive cloacal culture during the 18 days of
observation, while 93% (14 of 15) of the vaccinated turkeys had no cloacal shedding during
these 18 days. There was no correlation between titres and protection. Neither there was no
difference in the degree of protection between delivery systems, but gene gun delivery of DNA
was most efficient, since it required 100 times less DNA than the saline inoculations (2 µg
opposed to 200 µg of DNA) (Vanrompay, Cox et al. 1999). This study has been followed by
other comparing a combined parenteral (IM) and mucosal (IN) route to three other different
routes of administration (IM, IN and aerosol) and the effect of turkey interferon gamma on
genetic immunization. A significant level of protection was observed in turkeys immunized via
the combined IM/IN route, the IM route or by aerosol. Severe clinical signs and lesions were
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observed in the non-vaccinated control groups, in 80% of turkeys inoculated with MOMP and
interferon gamma DNA, and in 60% of turkeys vaccinated with MOMP DNA IN (Vanrompay,
Cox et al. 2001). The latest study compared three vaccination strategies: priming and boosting
with MOMP DNA, priming and boosting with recombinant MOMP and priming with MOMP
DNA followed by boosting with recombinant MOMP. The immunomodulating effect of 1 alpha,
25-dihydroxyvitamin D3 was also evaluated. Turkeys primed with MOMP DNA showed
significant protection against C. psittaci challenge, turkeys primed with recombinant MOMP did
not. The steroid hormone 1 alpha, 25-dihydroxyvitamin D3 augmented serum and mucosal
antibody titres. However, higher antibody titers were not related to better protection and even
had a negative effect specially on bacterial excretion (Verminnen, Van Loock et al. 2005).
Turkey chicks inoculated with plasmid MOMP DNA of C. psittaci serovar D were
evaluated for the influence of maternal antibodies on C. psittaci-specific immune responses. The
vaccinated groups, received DNA immunizations at 7 days and 3 weeks later, using a combined
IM and intranasal routes. Both T helper and B cell memory were primed. However, high
maternal antibodies titres affected the induction of vaccine-specific antibody responses as
assessed by MOMP-specific antibody levels in enzyme-linked immunosorbent assay (ELISA).
Cell-mediated immunity was unaltered as demonstrated by the significantly heightened
proliferative responses of the peripheral blood lymphocytes (PBL) following vaccination. The
DNA immunizations, could significantly reduce clinical signs, pharyngeal and cloacal excretion
as well as C. psittaci replication, even in the presence of maternal antibodies (Van Loock,
Lambin et al. 2004).
Turkeys inoculated with plasmid MOMP DNA of C. psittaci serovar D were evaluated
for the duration of the immune response against the vaccine. Over a period of 11 weeks, cellular
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uptake of the DNA vaccine was examined by PCR, transcription of the insert by reverse
transcript-PCR (RT-PCR) and a mRNA by immunofluorescence staining of muscle biopsies. The
results indicated that DNA vaccine persists in turkey muscle for at least 10 weeks, and during
that period the MOMP was continuously expressed, as evidenced by the immunofluorescence
staining and RT-PCR. (Loots, Vleugels et al. 2006)
Turkeys inoculated with plasmid MOMP DNA of C. psittaci serovar D and recombinant
MOMP with or without the immunomodulating CpG olignucleotides (CpG ON), were tested for
their ability to elicit an immune response and to induce protection against homologous challenge.
Two CpG ON were chosen for in vivo application based on their in vitro capacity to stimulate
the production of nitric oxide (NO) in chicken macrophages and their in vitro capacity to induce
turkey lymphocyte proliferation. Although the CpG ON induced a significant in vitro response,
the presence of the CpG ON as an adjuvant generated no significant effect on the immune
response or on the protective capacity of the tested vaccination methods. (Loots, Loock et al.
2006)
Chicks were inoculated IM with 106, 108 and 1010 50% culture infectious dose (TCID50)
of recombinant adenovirus containing the MOMP gene (rAd-MOMP). The MOMP gene was
amplified by PCR and cloned into the transfer vector pShuttle-CMV. The recombinant plasmid
was obtained by recombination between the plasmid pShuttle-CMV-MOMP and skeleton vector
pAdEasy-1 in E. coli strain BJ5183. The titer of the recombinant adenovirus containing the
MOMP gene of C. psittaci was 3.4 x 1010 TCID50/ml in human embryonic kidney 293 (HEK293)
monolayer cells. The expression of the MOMP in HEK293 cells infected with the rAd-MOMP
was confirmed by a indirect immunofluorescence assay. Inoculated chicks generated antibodies
against MOMP of C. psittaci detected by hemagglutination test, and a significant lymphocyte

42

proliferation response. Twenty-one days after immunization, the chicks were challenged by IN
route with 1.1 x 1011 ELD50 of a C. psittaci isolate. Nine out of 10 chicks in the vaccinated group
were protected, while chicks in the wild-type adenovirus control group and the PBS control
group all showed clinical signs after challenge. In post-mortem exam, all birds from the wildtype adenovirus and PBS control groups showed pneumonia, pericarditis, hepatosplenomegaly
and renal congestion, while nine out of 10 birds from the vaccinated had none of the pathological
lesions mentioned above at the end of the study on day 180 post-challenge. (Zhou, Qiu et al.
2007).
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CHAPTER THREE
MATERIALS AND METHODS

3.1 Objective and Hypothesis
The objective of this randomized controlled clinical trial was to assess the efficacy of
two recombinant DNA vaccines against C. psittaci in cockatiels (Nymphicus hollandicus). The
first recombinant DNA vaccine has a gene encoding MOMP and the immunostimulant
chitosan (MOMP DNA vaccine). The second recombinant DNA vaccine, contained the gene
encoding MOMP that is vectored by a human adenovirus (adeno-MOMP vaccine). The
hypothesis of this study was that the vaccines would induce a protective immunoresponse in
the vaccinated groups, preventing clinical signs, lesions and C. psittaci excretion in the cockatiel
model for C. psittaci infection.
3.2 Study Design
The study was approved by LSU Institutional Animal Care and Use Committee
(IACUC). Forty adult cockatiels (Nymphicus hollandicus) of unknown age or gender were used
for this study. The birds were given a complete physical exam to determine their general health
status, identified individually with a numbered wing band. The animals were tested for C.
psittaci using an indirect fluorescent antibody serologic test (IFA) to measure the presence of
antichlamydial antibodies (Ig G), and polymerase chain reaction (PCR) from whole blood and
combined choanal-cloacal swabs (Fudge 1997). The blood samples were collected using a one
handed draw technique from the right jugular vein, with a 3 ml syringe and 26 G needle. The
samples were centrifuged at 8000 rpm for 10 min and transferred to Eppendorf tubes and kept
refrigerated at 5ºC until submission the next day. The samples for IFA and PCR were submitted
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within 24 hours of sampling by overnight mail with frozen gel packs to the Emerging Disease
Research Group at the University of Georgia College of Veterinary Medicine. The birds selected
for the study were negative to the IFA and PCR from whole blood and combined choanalcloacal swabs. The birds were treated with doxycycline hyclate in the drinking water
(400mg/L) for 45 days, and a 2 month period of washout was allowed before initiating the
study.
The birds were housed individually in cage racks in 3.0x4.6 m laboratory animal rooms
in a restricted access area biosecurity level II at LSU. The control groups were housed in
individual rooms separated from the vaccine groups room. The birds were offered ad lib
commercial cockatiel seed mix and water in plastic containers. Fluorescent lighting was
maintained on an automatic timer with a 12 hour photoperiod.
The forty birds were randomly assigned to four different groups of ten birds using a
random number generator:
- 1- DNA MOMP vaccine group. The vaccine contained chitosan as an immunostimulant and
was administered combining intranasal (IN) (50µg-0.05 ml) and intramuscular (IM) (100µg-0.1
ml)) routes.
- 2- Adeno-MOMP vaccine group. The vaccine was administered combining IN (106 IU0.1ml) and intracoelomic (IC) (2x 106 IU-0.2ml) routes.
- 3- Negative control group of the adeno-MOMP vaccine. Vaccinated with adeno-MOMP
vaccine combining IN (106 IU-0.1ml) and IC (2x 106 IU-0.2ml) routes.
- 4- Positive control group, vaccinated with 0.9 % NaCl combining IN (0.1 ml) and IC (0.2
ml) routes.
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Figure 3.3-. Intranasal administration of the placebo in a cockatiel

The vaccines were developed by the Laboratory of Biomedical Sciences at Louisiana
State Univeristy (LSU) School of Veterinary Medicine and the Emerging Disease Research
Group at the University of Georgia College of Veterinary Medicine.
DNA from C. psittaci was used as template in order to amplify MOMP gene by PCR
using gene specific primers (Zhang et al. 1989, Chouljenko et al. 1996). The PCR product was
purified by agarose gel electrophoresis and used for cloning into pcDNA3.1/V5-His TOPO
vector (Invitrogen) as described in the manufacture’s instruction. Large scale plasmid DNA
preparation was produced using Qiagen purification kit.
The adeno MOMP vaccine was originated from plasmid DNA containing a MOMP
gene (DNA MOMP) used as template to amplify MOMP gene by PCR using gene specific
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primers that contained restriction endonuclease recognition sites BstB I at 5’ end and Xba I at 3’
end of the MOMP gene respectively. Human adenovirus type 5 (Ad5)-replication defective
constructs contain deletions in the E1and E3 gene region of approximately 3000 bp, resulting in
virus that can only replicate in cells stably transfected with the E1 region of the adenovirus
genome (i.e., 293 cells). Plasmid pAd5-Blue (37158 bp) includes most of the adenovirus genome
and two gene cassettes containing different genetic elements. Bacterial origin of replication and
kanamicin resistance genes are flanked by Pac I restriction sites and the right (RITR) and left
(LITR) inverted terminal repeat regions of Ad5. LacZ and ampicillin resistance genes are
located downstream of CMV promoter and are flanked by unique Cla I and Xba I restriction
sites. Construction of recombinant adenovirus require the digestion of the gene of interest with
Cla I or Cla I-compatible restriction endonucleases ( Acl I, BstB I, Nar I, BsaH I, HinP1 I, Hpa I,
and Taq I at the 5’ end of the gene) and Xba I or Xba I-compatible restriction endonucleases (
Avr II, Nhe I, and Spe I at the 3’ end of the gene). Typically these sites can be introduced by
PCR and site choices are determined by nucleotide sequence of the gene of interest. (BstBI and
XbaI sites were used for cloning of MOMP gene). After Pac I restriction (to drop out Km
resistance and bacterial ori of replication) linearized pAd5-Blue-recombinant plasmid DNA (4
µg for each well of 6-well plate) was transfected into 293 cells using Lipofectamin 2000. After 5
days of incubation transfected cells were subjected to 5 times of freeze and thaw cycle and an
aliquot was used for next passage by infection of fresh 293 cells. By passage number four, titers
of recombinant adenovirus were around 108 and ready to be used for animal immunizations.
The animals were vaccinated on days 0 and 21 with the corresponding vaccine (DNA
MOMP vaccine group, adeno-MOMP vaccine group, negative control group) or placebo
(positive control group), and both vaccine groups and the positive control were challenged on
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day 42 receiving 0.1 ml of incoculum IN containing approximately 106 C. psittaci live
organisms with a 1 ml syringe and a 26 G needle. The negative control group was not
challenged with any live organisms.
The organisms used to infect the birds corresponded to LSU isolate 84-1832 from a
cockatiel diagnosed with avian chlamydiosis. The original challenge stock was low-passage
grown in the yolk-sacs of embryonated hen’s eggs. Stock was prepared and was titrated to about
1.25 x 107 infectious units/mL. For titration of an aliquot of challenge stock was thawed and used
to make ten-fold dilutions. Two-tenths (0.2) mL of each dilution were inoculated into one-day
old monolayers of Vero cells, which had been established in 12 mm diameter shell vials using
bicarbonate-buffered MEM cell culture media containing aminoglycoside antibiotics. Following
30 minutes of centrifugation at 35-37°C, the inocula were removed, and the culture vials were
rinsed and replenished with MEM containing 2% fetal bovine serum and 2 mg/mL
cycloheximide. At 72 hours post-inoculation, coverslips containing inoculated, monolayered
cells were saline-rinsed and acetone-fixed. The fixed cells were stained with direct
immunofluorescent conjugate (source, NVSL, Ames, IA) for 30 min at 37°C. The stained
coverslips were mounted onto microscope slides and were evaluated for fluorescent foci with a
darkfield epifluorescent microscopy at 400 X magnification. The number of infectious
chlamydophila organisms within the original inoculation volume was determined by counting
fluorescent foci in several representative fields (10), determining the average number per field,
multiplying this number by the approximate number of field areas in a 12 mm coverslip, and
then multiplying by the dilution factor. Only those dilutions giving fluorescent foci counts of 10100 per field are used in this calculation. The stock was stored at -70ºC for 10 months until it
was administered to the birds.
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The birds were tested for antichlamydial antibodies (IFA) prior to being booster on day
21, and being challenged with C. pisttaci live organisms on day 42. Traditional IFA methods
were utilized in this assay. Chlamydial infected McCoy cells were grown on multimicrowell
IFA slides under 5% CO2 and 37oC in supplemented Eagles media. After reaching the inclusion
stage of infection, slides were fixed in acetone and stored at -70oC until use. To perform the test,
slides were warmed to room temperature and PBS diluted samples were overlayed. After
incubation and wash, a FITC conjugated polyclonal antisera was incubated for an additional
period. Slides were washed and counterstained. The antisera was previously prepared in a rabbit
using a mixture of psittacine sera. The antisera was partially purified and conjugated with FITC.
The antisera has been found to be reactive with multiple psittacine and non-psittacine species via
radial immunodiffusion studies (data not shown). Other antisera used in this study includes FITC
anti-chicken IgG (Sigma, St. Louis, MO). Specific reactivity was evaluated by fluorescence
microscopy versus positive and negative controls as well as the use of a cross reactive FITC
conjugated monoclonal antibody to Chlamydia trachomatis (VWR, Atlanta, GA) LPS epitope (a
shared antigen with other species of Chlamydia.
The animals were monitored daily for the presence of rhinitis, conjunctivitis, dyspnea,
diarrhea and depression. The clinical signs were graded as absent (0), mild (1), moderate (2) or
severe (3). On days 46, 49, 52, 55, 70 and 82, combined choanal and cloacal swabs were taken
and submitted for C. psittaci PCR. The surviving birds were tested on day 82 for antichlamydial
antibodies (IFA) and for the presence of C. psittaci (PCR) from whole blood and combined
choanal-cloacal swabs, and then humanely euthanized.
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r
jugular vein in a cockatiel.
Figure 3.4-- Blood sampple collectioon from the right

C
swabb collection for C. psittaaci PCR.
Figure 3.5- Choanal
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Figure 3.6- Cloacal swab collection for C. psittaci PCRl.

The birds were submitted for necropsy and examined for the presence of macroscopic
lesions on conjuntiva, lungs, airsacs, heart, spleen and liver. The findings were graded as
absent (0), mild (1), moderate (2) or severe (3). Individual samples from each of those tissues
were taken for histopathology and pooled samples were submitted for C. psittaci culture. The
results of the culture were reported as positive or negative. The lesions from histopathology were
graded as absent (0), minimal (1), mild (2), moderate (3) or severe (4). For C. psittaci culture,
tissue specimens were homogenized in a phosphate-buffered sucrose solution containing
aminoglycoside antibiotics to a final, approximate dilution of 10-15%. The homogenate was
centrifuged at 800 x g for 30 minutes. An aliquot of each supernate was removed and used to
inoculate a set of one-day old Vero cell cultures monolayered in shell vials. Control specimens
(positive and cell culture media negative) were inoculated into shell vials similar to the tissue
homogenates. Inoculated shell vials were centrifuged at 800 x g for 30 minutes at 35-37°C. The
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vials were then rinsed and replenished with culture medium containing 2% fetal bovine serum
and 2 mg/mL cycloheximide. At three days post-inoculation, one vial of each set was acetonefixed and stained by direct immunofluorescence with the Chlamydophila conjugate. The
approximate number of infectious foci was determined for each specimen found positive on
initial culture. A cell scraping was collected from each negative culture and used as inoculum for
sub-culture, performed and evaluated as primary attempts, except sub-cultures were determined
either positive or negative without quantification.
3.3 Statistical Analysis
The 95% binomial confidence intervals were calculated for each prevalence estimate
(data not reported). To evaluate the study differences over time, a Cochran’s Q test was used for
dichotomous data (e.g., PCR) and a Friedman’s nonparametric test was used for ordinal data
(e.g., antibody titers, clinical signs, necropsy, histopathology). A chi square test (4 x 2) was used
to determine if there were differences between study groups when the outcome variable was
dichotomous (e.g. PCR, culture). When differences were present, a Fisher exact test was used to
further elaborate the difference. A Kruskal-Wallis test was used to determine if there were
differences between ordinal data by group (e.g., antibody titers, clinical signs, necropsy,
histopathology). When differences were present, a Mann-whitney was used to elaborate further
differences. SPSS 11.0 (SPSS Inc., Chicago, IL) was used to analyze the data. A p<0.05 was
used to determine statistical significance.
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CHAPTER FOUR
RESULTS
There was no significant difference in mortalities between the four groups, and only one
bird from the negative control (*prior to challenge) and one bird from each of the vaccine
groups (adeno-MOMP and MOMP DNA groups) died during the study.
Table 4.1- Mortality within the different vaccine and control groups
Mortality

Survive

Died

Adeno-MOMP

9

1

Positive control

10

0

Negative control

9

1*

DNA MOMP

9

1

Group

There were no significant differences between the four groups including conjunctivitis
(p=0.20), rhinitis (all negative), diarrhea (p=0.25), dyspnea (p=0.6) and mentation (p=0.6),
although there were significant differences in biliverdinuria between positive and negative
controls (p=0.05), adeno-MOMP and MOMP DNA groups (p=0.035) and negative control and
MOMP DNA group (p=0.003).
There were no significant differences in antibody titers between the four groups
on days 21 and 42. There were no significant differences over time for any of the groups for
antibody titer between day 21 and day 42 (negative p=1.0, positive p=0.31, MOMP DNA p=1.0,
adeno-MOMP p= 0.31), but there were between day 21, 42 and day 84 in all the groups (positive
p= 0.04 , MOMP DNA p=0.02, adeno-MOMP p=0.04) except the negative control (p=0.18).
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Table 4.2- Clinical signs within different vaccine and control groups
Clinical signs
Group

Biliverdinuria

Conjuntivitis

Diarrhea

Dyspnea Depression

Adeno-MOMP

2(1)

4(1), 1(2)

1(1)

1(2)

1(1),1(2)

4(1),1(2)

8(1)

1(1)

0

0

2 (1)

0

0

0

0

5(1)

4(1), 1(2)

2(1)

1(1)

1(2)

(n=10)
Positive
control (n=9)
Negative
control(n=10)
DNA
MOMP(n=10)
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Figure 4.1- A bright and alert,
a
and a mentally
m
deppressed cockkatiel (left annd right
respectivvely).

Figre 4.2- A cockatiel with
w normal eyes, and one with moderate conjuuntivitis (lefft and
right resppectively).
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Figure 4.3- A cockatiel with
w normal nostrils,
n
and one with mooderate rhiniitis (left andd
right resppectively).

mal feces annd unformedd feces with biliverdinurria (left and right
Figuree 4.4 - Norm
respectivvely).
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Table 4.3, 4.4 and 4.5 - Antibody titers by IFA 21m 42 and 84 days after booster.
Table 4.3
Day 21
Titer

Negative

1:05

1:25

1:50

Adeno-MOMP

7

1

2

0

Positive control

10

0

0

0

Negative control

9

0

0

0

DNA MOMP

10

0

0

0

Negative

1:05

1:25

1:50

Adeno-MOMP

8

0

2

0

Positive control

9

1

0

0

Negative control

9

0

0

0

DNA MOMP

10

0

0

0

Negative

1:05

1:25

1:50

Adeno-MOMP

2

2

4

1

Positive control

4

2

3

0

Negative control

7

1

1

0

DNA MOMP

2

4

2

0

Group

Table 4.4
Day 42

Titer

Group

Table 4.5
Day 84

Titer

Group
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There was no significant difference in the number of PCR positive choanal-cloacal swabs
when comparing adeno-MOMP or DNA MOMP group and positive control, or adeno-MOMP
group and DNA MOMP group, but there was a significant difference (p=0.0001) when
comparing the negative control group and the remaining groups. There was significant difference
over time in the number of PCR positive choanal-cloacal swabs (p=0.0001). The blood samples
from day 82 submitted for PCR were negative in all the birds.
There was no significant difference between groups for the presence of macroscopic
lesions found at necropsy for the conjuntiva (all absent) and lungs (all absent), air sacs (p=0.3),
liver (p= 0.3) and pericardium (p=0.6). There was a difference between groups in lesions
associated with the spleen (p=0.001). There was no significant difference when comparing
positive control and negative control (p=0.06), and positive control and adeno-MOMP group
(p=0.9), but there was significant differences between adeno-MOMP group and negative control
(p=0.02), adeno-MOMP group and MOMP DNA group (p=0.02), MOMP DNA group and
positive control (p=0.05), and MOMP DNA group and negative control (p=0.001).

Table 4.6- Macroscopic lesions seen in spleen within the different vaccinated and control
groups.
Spleen

Grade

Absent

Mild

Moderate

Severe

Adeno-MOMP

4

6

0

0

Positive control

5

4

0

1

Negative control

10

0

0

0

DNA MOMP

1

4

5

0

Group
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Figure 4.5- Normal
N
liver and liver wiith severe paathology on necropsy
n
(left and right
respectivvely).

Figure 4.6- Normal
N
heartt and heart with
w severe pathology
p
onn necropsy (lleft and rightt
respectivvely).
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Figure 4.7- Normal
N
air sacs
s
and air sacs
s
with sevvere patholoogy on necroopsy (left andd
right resppectively).

Figure 4.8- Normal
N
spleeen and severrely enlargedd spleen on necropsy
n
(leeft and right
respectivvely).
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The histopathologic results from the negative control group:
-

06R 088 bird 637. Eyelid: moderate lymphocytic conjunctivitis; locally extensive

lymphocytic submucosal inflammation forming a plaque like elevation with slight infiltration of
the mucosa. Liver: moderate multifocal lymphocytic follicular hepatitis with extramedullary
hematopoiesis; numerous prominent inflammatory aggregates that are fairly well circumscribed
with many of these containing lymphoid follicles and a peripheral layer of mixed inflammatory
cells believed to represent extramedullary hematopoiesis. Spleen: moderate splenic lymphoid
hyperplasia; moderate lymphoid hypercellularity with numerous sometimes large lymphoid
follicles and early germinal center formation. Lung, heart: no significant lesions
-

06R 088 bird 680. Liver: minimal multifocal lymphocytic hepatitis; few multifocal

inflammatory cell aggregates consisting mostly of lymphocytes and plasma cells with a random
distribution pattern. Lung, eyelid, spleen, heart: no significant lesions.
-

06R 088 bird 681. Eyelid: mild chronic conjunctivitis; infiltration of lymphocytes, few

heterophils and rare macrophages in the submucosa with some disruption of the mucosa. Liver:
possible extramedullary hematopoiesis versus mild multifocal chronic mixed hepatitis;
multifocal inflammatory cell aggregates consisting of plasma cells, lymphocytes, rare heterophils
are noted especially in portal areas. Lung, spleen, heart: no significant lesions.
-

06R 088 bird 691. Liver: mild chronic multifocal mixed hepatitis; multifocal poorly

circumscribed inflammatory cell aggregates consisting of mixed inflammatory cells often in
portal areas but also around vessels. Lung, spleen, eyelid, heart: no significant lesions.
-

06R 088 bird 693. Eyelid: mild lymphocytic conjunctivitis: minimal lymphocytic

infiltration in the superficial submucosa with a focal area of heavy lymphocytic accumulation.
Liver: possible extramedullary hematopoiesis versus mild chronic multifocal mixed hepatitis:
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multifocal prominent fairly well-circumscribed inflammatory cell aggregates of mixed
inflammatory cells primarily in a portal distribution but sometimes associated with
lipogranulomas. Lung (incidental pneumoconiosis), spleen, heart: no significant lesions.
-

06R 088 bird 698. Eyelid: minimal chronic conjunctivitis: minimal infiltration of

primarily lymphocytes around submucosal vessels and occasionally in the superficial
submucosa. Liver: mild multifocal chronic hepatitis: rare multifocal small inflammatory
aggregates of mixed inflammatory cells that are not well circumscribed and appear randomly
scattered throughout the lobules. Lung, pancreas, spleen, heart: no significant lesions.
-

06R 088 bird 980. Spleen: mild splenic lymphoid hyperplasia; mild lymphoid hyperplasia

with increased lymphoid follicles and germinal center formation. Liver: fatty liver and probable
extramedullary hematopoiesis versus mild multifocal mixed hepatitis; prominent diffuse
vacuolation of hepatocytes consistent with lipid accumulation, multifocal fairly well
circumscribed inflammatory cell aggregates consisting of mixed inflammatory cells (heterophils,
lymphocytes, plasma cells and larger mononuclear cells). Eyelid: minimal chronic conjunctivitis;
minimal inflammatory cell infiltration in the superficial submucosa sometimes extending into the
mucosa. Lung, heart: no significant lesions.
-

06R 088 bird 982. Liver: mild multifocal chronic mixed hepatitis; multifocal well-

circumscribed inflammatory cell aggregates mainly in a portal distribution pattern, mixed cell
types including lymphocytes, heterophils, plasma cells and possible rare macrophages. Spleen:
mild splenic lymphoid hyperplasia; diffuse lymphoid hyperplasia. Eyelid: moderate unilateral
follicular lymphocytic conjunctivitis; one eyelid is characterized by prominent lymphoid follicles
in superficial submucosa. Lung, heart: no significant lesions.
-

06R 088 bird 985. Liver: mild multifocal lymphocytic hepatitis; a few scattered
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inflammatory aggregates varying in size with some consisting mostly of lymphocytes but
occasionally having heterophils and plasma cells with a random distribution pattern.
Lung, eyelid, spleen, heart: no significant lesions.
-

06R 088 bird 999. Lung, spleen, eyelid, liver, heart: no significant lesions.

The histopathologic results from the positive control group:
-

06R 093 bird 633. Liver: mild multifocal mixed hepatitis: several randomly scattered

inflammatory foci consisting of lymphocytes, plasma cells; periportal inflammatory aggregates
of lymphocytes, plasma cells and heterophils with possible macrophages. Eyelid: mild to
moderate lymphocytic conjunctivitis; prominent submucosal infiltration of lymphocytes with
some exocytosis into the mucosal layer. Spleen: mild to moderate lymphoid hyperplasia of
spleen; lymphoid hypercellularity especially around vessels with mild increase in lymphoid
follicles. Lung, skin heart: no significant lesions
-

06R 093 bird 636. Liver: moderate to severe multifocal mixed hepatitis with necrosis;

numerous multifocal inflammatory aggregates consisting of mixed cells (heterophils,
lymphocytes, plasma cells, macrophages) with necrosis of hepatocytes. Eyelid: diffuse severe
mixed conjunctivitis; diffuse submucosal infiltration of mixed inflammatory cells (lymphocytes,
plasma cells, heterophils) exocytosis into mucosal layer. Lung, heart: no significant lesions.
-

06R 093 bird 642. Spleen: mild lymphoid hyperplasia of spleen; mild lymphoid

hypercellularity numerous lymphoid follicles and/or germinal centers. Eyelid: minimal lymphoid
conjunctivitis and mild lymphoid hyperplasia of eyelid; focal plaque lymphoid hyperplasia with
follicle formation and mild lymphocytic to mixed infiltration in superficial submucosa with
exocytosis. Liver: minimal multifocal lymphocytic hepatitis; rare scattered inflammatory nodules
consisting mostly of lymphocytes with few macrophages. Lung, heart: no significant lesions.
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-

06R 93 bird 646. Liver: minimal multifocal lymphocytic to mixed hepatitis; scattered

multifocal inflammatory nodules consisting primarily of lymphocytes with lesser numbers
heterophils, macrophages and plasma cells. Spleen: moderate lymphoid hyperplasia of spleen;
moderate hypercellularity of lymphocytes with numerous lymphoid follicles. Eyelid: moderate
lymphocytic follicular conjunctivitis; plaque-like lymphocytic infiltration in the superficial
submucosa with formation of lymphoid follicles. Lung, heart: no significant lesions.
-

06R 093 bird 677. Eyelid: mild lymphocytic mixed conjunctivitis; mild infiltration of

lymphocytes with lesser numbers of plasma cells and few heterophils in submucosa with
exocytosis into the mucosal layer. Liver: moderate multifocal lymphocytic to mixed hepatitis;
several multifocal inflammatory cell aggregates often in a periportal distribution with some bile
duct hyperplasia and inflammatory cells (lymphocytes, heterophils, macrophages and plasma
cells). Air sac: moderate diffuse lymphocytic to mixed airsacculitis; fairly diffuse infiltration of
inflammatory cells (lymphocytes, heterophils, macrophages) in the submucosa with occasional
areas of exocytosis into the mucosal layer. Spleen: moderate lymphoid hyperplasia of spleen
with increased lymphoid follicles; mild lymphoid hypercellularity with increased numbers of
lymphoid follicles. Lung, heart: no significant lesions.
-

06R 093 bird 692. Spleen: moderate lymphoid hyperplasia of spleen with increased

lymphoid follicles; moderate lymphoid hypercellularity with numerous lymphoid follicles.
Eyelid: mild lymphocytic to mixed conjunctivitis; patchy mild areas of inflammatory cell
infiltration with some exocytosis into the mucosa and nflammatory cells (lymphocytes with
lesser numbers of heterophils and macrophages). Liver: mild multifocal lymphocytic to mixed
hepatitis; random multifocal inflammatory aggregates (mostly lymphocytes and some nodules
are lymphohistiocytic). Lung, heart: no significant lesions
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-

06R 093 bird 694. Eyelid: severe chronic mixed conjunctivitis; severe diffuse infiltration

of submucosa and mucosa with mixed population of inflammatory cells (lymphocytes,
heterophils, macrophages, few plasma cells) with extension into underlying muscle. Liver: mild
multifocal chronic mixed hepatitis; random multifocal inflammatory cell aggregates (mainly
lymphocytes and macrophages), often in a periportal location but sometimes in lobules with
disruption of hepatocytes. Spleen: marked lymphoid hyperplasia of spleen with increased
lymphoid follicles; marked lymphoid hyperplasia mainly seen as numerous large lymphoid
follicles. Lung, heart: no significant lesions.
-

969 believed to be 696. Spleen: mildly prominent periarteriolar macrophages sheaths.

Eyelid: scant edema, small focal area of superficial lymphocytes at and beneath mucosal layer.
Skin, liver, lung, pancreas, duodenum, heart: no significant lesions.
-

06R 093 bird 979. Spleen: moderate to severe lymphoid hyperplasia of spleen with

increased lymphoid follicles; lymphoid hyperplasia, diffuse, with increased numbers of lymphoid
follicles of varying sizes. Liver: minimal multifocal lymphohistiocytic hepatitis; few randomly
scattered small inflammatory foci consisting mainly of lymphocytes and macrophages. Eyelid:
minimal chronic mixed conjunctivitis; minimal infiltration of lymphocytes, plasma cells and
heterophils in the submucosa. Lung, heart: no significant lesions.
-

06R 093 bird 983. Spleen: moderate to severe lymphoid hyperplasia of spleen with

increased lymphoid follicles; diffuse lymphoid hypercellularity with increased lymphoid
follicles of varying sizes. Liver: mild multifocal mixed hepatitis; several randomly scattered
inflammatory foci with some disruption of hepatocytes, mixed inflammatory cells including
lymphocytes, heterophils, macrophages. Eyelid: moderate diffuse lymphocytic to mixed
conjunctivitis: moderate diffuse infiltration of the submucosa by lymphocytes, plasma cells,
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macrophages and few heterophils. Lung, heart: no significant lesions.
The histopathologic results from the DNA vaccine group:
-

06R 093 bird 635. Eyelid: minimal lymphocytic conjunctivitis: minimal focal

lymphocytic infiltration of submucosa with some exocytosis of lymphocytes into mucosa.
Liver: mild multifocal lymphohistiocytic hepatitis; randomly scattered inflammatory cell foci
consisting mostly of lymphocytes and macrophages. Spleen: mild to moderate lymphoid
hyperplasia of spleen; mild to moderate lymphoid hypercellularity consisting mostly of
perivascular hypercellularity with formation of rare lymphoid follicles. Lung, heart: no
significant lesions.
-

06R 093 bird 638. Spleen: severe lymphoid hyperplasia of spleen with formation of

numerous lymphoid follicles; marked lymphoid hypercellularity of spleen characterized mostly
by formation of lymphoid follicles that are almost contiguous throughout the spleen. Liver:
moderate multifocal lymphocytic hepatitis; frequent multifocal lymphocytic inflammatory
nodules of varying size scattered throughout the liver. Eyelid: severe diffuse lymphocytic to
mixed conjunctivitis with formation of numerous lymphoid follicles; severe diffuse infiltration of
lymphocytes throughout the submucosa with prominent exocytosis into mucosa and formation of
numerous lymphoid follicles (scattered heterophils as well as few plasma cells and macrophages
are also seen). Lung, air sac, heart: no significant lesions.
-

06R 093 bird 644. Spleen: moderate lymphoid hyperplasia spleen with congestion;

moderate lymphoid hypercellularity of spleen mainly as perivascular hypercellularity with
formation of few lymphoid follicles, moderate congestion of red pulp. Liver: mild multifocal
lymphohistiocytic hepatitis; randomly scattered inflammatory foci consisting mostly of
lymphocytes macrophages throughout liver. Eyelid: mild lymphocytic to mixed conjunctivitis;
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mild infiltration of lymphocytes with scattered heterophils in submucosa with some exocytosis
into mucosa. Lung, air sac, heart: no significant lesions
-

06R 093 bird 645. Spleen: mild to moderate lymphoid hyperplasia; mild to moderate

lymphoid hypercellularity mainly around vessels but also with formation of few lymphoid
follicles. Liver: mild multifocal lymphocytic hepatitis; scattered lymphocytic aggregates
throughout liver parenchyma. Eyelid: mild to moderate lymphocytic to mixed conjunctivitis;
focally diffuse area of lymphocytic to plasmacytic infiltration in the submucosa with scattered
heterophils and exocytosis into mucosa. Lung, air sac, heart: no significant lesions
-

06R 093 bird 682. Spleen: moderate splenic congestion. Liver: minimal multifocal

lymphocytic to mixed hepatitis; autolysis precludes critical evaluation however, there are
scattered multifocal lymphocytic to mixed inflammatory cell aggregates with some disruption of
the parenchyma. Eyelid: minimal mixed conjunctivitis; minimal interstitial filtration of the
submucosa by lymphocytes, plasma cells, few heterophils and few macrophages. Lung, heart: no
significant lesions
-

bird 688. Liver: mild chronic hepatitis inflammatory cell infiltration primarily

subcapsular but also in spaces of disse and occasionally within sinusoids; inflammatory cells are
of mixed cell types including blast cells probably indicating extramedullary hematopoiesis and
individual hepatocellular vacuolation and degeneration with some apoptosis. Eyelid: minimal
chronic mixed conjunctivitis: infiltration of mixed inflammatory cells including heterophils,
lymphocytes and macrophages in the mucosal layer and submucosa. Heart, lung: no significant
lesions.
-

06R 093 bird 697. Spleen: moderate lymphoid hyperplasia of spleen with few follicle

formation: moderate lymphoid hypercellularity primarily as perivascular hypercellularity with
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few lymphoid follicles, moderate congestion of red pulp. Liver: minimal multifocal lymphocytic
to mixed hepatitis; rare scattered inflammatory cell foci consisting mostly of lymphocytes but
also containing macrophages, plasma cells and few heterophils. Lung, eyelid, heart: no
significant lesions.
-

06R 093 bird 981. Liver: mild multifocal lymphohistiocytic hepatitis; few scattered

random inflammatory cell foci consisting mostly of lymphocytes and macrophages. Spleen:
moderate to severe lymphoid hyperplasia of spleen with lymphoid follicle formation; moderate
lymphoid hypercellularity of spleen with numerous lymphoid follicle formation. Eyelid: severe
diffuse lymphocytic to mixed conjunctivitis; diffuse submucosal infiltration of lymphocytes,
macrophages, few plasma cells and few heterophils with exocytosis of mainly heterophils into
the mucosa. Lung, heart: no significant lesions.
-

06R 093 bird 986. Eyelid: scant chronic heterophilic conjunctivitis; scant infiltration of

mainly heterophils and lymphocytes submucosa with exocytosis into mucosa. Liver: mild
multifocal lymphohistiocytic hepatitis; randomly scattered inflammatory cell foci throughout
liver consisting mostly of lymphocytes and macrophages. Spleen: moderate splenic congestion.
Lung, heart: no significant lesions.
-

06R 093 bird 987. Eyelid: mild lymphocytic and mixed conjunctivitis with rare lymphoid

follicle formation; mild infiltration of lymphocytes with scattered heterophils and plasma cells in
submucosa with some exocytosis into mucosa and rare lymphoid follicle formation. Liver:
moderate multifocal lymphohistiocytic hepatitis; frequent multifocal inflammatory cell
aggregates throughout parenchyma consisting mainly of lymphocytes and macrophages. Spleen:
mild lymphoid hyperplasia spleen with mild capsulitis; mild lymphoid hypercellularity with few
lymphoid follicles. The capsule/serosa contains increased numbers of inflammatory cells
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(mostly lymphocytes and macrophages with scattered heterophils). Lung, heart: no significant
lesions.
The histopathologic results from the adeno-MOMP vaccinel group:
-

06R 093 bird 630. Eyelid: mild lymphocytic conjunctivitis with lymphoid follicle

formation; mild localized interstitial lymphocytic infiltration of the superficial submucosa with
formation of several lymphoid follicles and some exocytosis into the mucosa. Liver: minimal
multifocal lymphocytic hepatitis; rare lymphoid follicles are noted in the parenchyma. Spleen,
lung, heart: no significant lesions.
-

06R 093 bird 634. Spleen: moderate lymphoid hyperplasia of spleen with increased

follicle formation; moderate lymphoid hypercellularity with increased lymphoid follicles. Liver:
minimal multifocal lymphohistiocytic hepatitis; few randomly scattered inflammatory foci
consisting mostly of lymphocytes and macrophages. Eyelid: minimal lymphocytic localized
conjunctivitis; focal area of submucosal lymphocytic infiltration with exocytosis into the
mucosa. Lung, heart: no significant lesions.
-

06R 093 bird 639. Spleen: moderate lymphoid hyperplasia of spleen; moderate lymphoid

hypercellularity with formation of few lymphoid follicles. Liver: minimal multifocal mixed
hepatitis: rare scattered inflammatory foci consisting of mixed inflammatory cells (macrophages,
heterophils, lymphocytes). Eyelid: minimal focal lymphocytic conjunctivitis; focal area of
lymphocytic infiltration in submucosa with rare lymphoid follicles and mild exocytosis of
lymphocytes into the mucosa. Lung, heart: no significant lesions.
-

06R 093 bird 640. Eyelid: mild to moderate lymphocytic to mixed conjunctivitis: diffuse

lymphocytic to mixed infiltration in the submucosa with focally intense area of inflammation.
exocytosis of lymphocytes and heterophils two mucosa. Liver: minimal multifocal
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lymphohistiocytic hepatitis; several randomly scattered inflammatory foci consisting mostly of
lymphocytes and macrophages. Spleen: moderate to severe lymphoid hyperplasia of spleen with
formation of numerous follicles; diffuse lymphoid hypercellularity with formation of numerous
lymphoid follicles of varying sizes. Lung, heart: no significant lesions
-

06R 093 bird 641. liver: minimal multifocal lymphocytic to mixed

hepatitis: randomly scattered inflammatory cell foci consisting of lymphocytes, heterophils,
macrophages and few plasma cells. spleen: severe lymphoid hyperplasia of spleen with
formation of numerous follicles: severe diffuse lymphoid hypercellularity of spleen with
numerous follicles that are almost continuous throughout the spleen.eyelid: mild to moderate
lymphocytic to mixed conjunctivitis with formation of lymphoid follicles: large patchy areas of
lymphocytic infiltration and submucosa with formation of lymphoid follicles. heterophils are
often mixed with the lymphocytes, and exocytosis of lymphocytes and heterophils is noted in the
mucosa.lung, heart: no significant lesions.
-

06R 093 bird 643. Liver: minimal multifocal lymphocytic hepatitis; rare lymphoid

nodules scattered randomly in the liver. Spleen: moderate lymphoid hyperplasia of spleen with
formation of lymphoid follicles; moderate lymphoid hypercellularity and spleen mainly as
perivascular accumulations with formation of few lymphoid follicles. Eyelid: mild lymphocytic
to mixed conjunctivitis; patchy areas of lymphocytic infiltration into the superficial submucosa
with exocytosis into the mucosa, scattered heterophils accompany lymphocytes. Lung, heart: no
significant lesions.
-

06R 093 bird 678. Spleen: moderate lymphoid hyperplasia of spleen; moderate lymphoid

hypercellularity spleen with rare follicle formation. Eyelid: minimal lymphocytic conjunctivitis;
minimal infiltration of lymphocytes in submucosa with slight exocytosis into the mucosa. Liver:
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minimal multifocal lymphohistiocytic hepatitis; rare scattered inflammatory foci consisting
mostly of lymphocytes and macrophages. Air sac, lung, heart: no significant lesions.
-

06R 093 bird 679. Liver: mild multifocal lymphocytic to mixed hepatitis; randomly

scattered inflammatory cell foci consisting mostly of lymphocytes along with heterophils and
few plasma cells. Spleen: moderate lymphoid hyperplasia of spleen with mild capsulitis; mild
diffuse lymphoid hypercellularity of spleen with al follicle formation, mild disruption of capsule
by macrophages and lymphocytes. Eyelid: mild lymphocytic to mixed conjunctivitis; mild
infiltration of lymphocytes with scattered heterophils and plasma cells in superficial submucosa
with exocytosis into mucosa. Lung, heart: no significant lesions
-

bird 689. Spleen: mild splenitis and hemosiderosis; increased numbers of

plasma cells, mild to moderate hemosiderosis, increased numbers of macrophages containing
globular eosinophilic material, background of globular eosinophilic material probably indicating
fibrin, lack of distinct lymphocytic follicles. Liver: severe necrotizing hepatitis; marked
disruption of normal architecture due to patchy hepatocellular degeneration and necrosis,
multifocal inflammatory cell infiltration (mostly lymphocytes and plasma cells) with bile duct
proliferation and portal fibrosis, individual hepatocytes/kupffer cells contain basophilic granular
material probably representing micro-colonies, scattered hemosiderophages throughout liver.
Eyelid: severe chronic mixed conjunctivitis; severe inflammatory cell for infiltration of mucosa
and superficial submucosa, cells include lymphocytes, plasma cells, macrophages and rare
heterophils. Lung, heart: no significant lesions.
-

06R 093 bird 695. Liver: mild multifocal lymphohistiocytic hepatitis; randomly scattered

inflammatory cell foci consisting mostly of lymphocytes macrophages. Spleen: moderate
lymphoid hyperplasia of spleen with formation of numerous follicles; moderate lymphoid
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hypercellularity and spleen consisting predominantly of numerous lymphoid follicles. Lung, air
sac, eyelid, heart: no significant lesions.
There were no significant differences between groups for the presence of microscopic
lesions in the heart (all absent), lungs (all absent), conjuntiva (p=0.2) and liver (p= 0.3) but there
was a difference between groups in lesions associated with the spleen (p=0.005). There were no
differences between Adeno-MOMP group and positive control (p=0.8), Adeno-MOMP and
DNA groups (p=0.7), and DNA group and positive control (p=0.8). There was a significant
difference in the spleens between Adeno-MOMP group (p=0.002), positive control (p=0.003)
and DNA group (p=0.02) with the negative control. There were only six air sac tissue samples
processed, and only one of them corresponding to the positive control had moderate
inflammation.

Table 4.7- Microscopic lesions seen in spleen within the vaccinated and control groups.
Spleen
Group

Grade

Absent

Minimal

Mild

Moderate

Severe

Adeno-MOMP

0

0

1

6

2

Positive control

1

0

1

4

3

Negative control

7

0

2

1

0

DNA MOMP

2

0

1

4

2
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Figure 4.11- Histopatholo
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Only two of the cultures were positive for C. psittaci, one from the adeno-MOMP group
and another from the MOMP DNA groups that died during the study.
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CHAPTER FIVE
DISCUSSION

In the present study, two recombinant vaccines were used to assess the potential for
protecting cockatiels against challenge of C. psittaci challenge. Efforts were made towards
improving the delivery of the recombinant DNA vaccine from previous studies, through new
routes of administration, immunostimulants and vectors. The MOMP DNA vaccine containing
chitosan was administered by a combined IM and IN route combining the benefits of unusually
efficient transfection and efficient antigen presentation at the mucosal site. Adeno-MOMP
vaccine was administered by a combined IC and IN route.
The Adeno-MOMP vaccine had previously undergone mouse experiment by IP, IN and
SQ inoculation, resulting all routes in production of antibody response to the adenovirus
antigens. The response to MOMP was not studied due to lack of good source of MOMP antigen
at that time.
The morbidity and mortality attributed to C. psittaci challenge in this study was minimal
and insufficient to establish significant differences between controls and vaccinated groups. One
exception was for the presence of biliverdinuria. The results of the samples submitted for C.
psittaci PCR during the study (positives in the challenged groups), and the antibody titers after
challenge (higher also in the challenged groups) confirmed that the inoculation with C. psittaci
was successful. The reasons that the animals were only found to have minimal morbidity and
mortality could be attributed to residual immunity due to previous exposure to C. psittaci,
residual antibiotic in tissue after pre-treatment with doxycicline or a shift in the pathogenicity of
the inoculum.
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The serum antibody response measured by IFA in both vaccine groups against C.
psittaci was not significant. The IFA test appears to detect primarly IgG. Sensitivity and
specificity varies with the immunoreactivity of the polyclonal antibody to various avian species.
Low titers may occur because non-specific reactivity (Smith, Bradley et al. 2006). The specific
sensitivity and specificity of the test has been estimated to be 48.3% and 96.4 % from clinical
cases (Cray, personal communication). Local antibody response and cellular immunity were
not measured in this study, and would have bring additional information about the
immunoresponse elicited by the vaccines. Serum and mucosal antibody levels have not been
correlated to a higher protection level in previous studies with turkeys (Vanrompay, Cox et al.
1999; Verminnen, Van Loock et al. 2005), and cell-mediated immunity is thought to play a
major role. In the murine model for C. trachomatis , CD4+ T helper type 1 (Th1), CD8+ T cells,
mononuclear phagocytes and cytokines secreted by these cells are considered potential effectors
of anti-chlamydial immunity (Johansson, Schon et al. 1997; Williams, Grubs et al. 1997). In the
guinea pig (Cavia caviae) infection model, both humoral and cell mediated immunity seem to be
important to clearing the infection and for resistance against reinfection (Rank, Soderberg et al.
1989).
The C.psittaci PCR from choanal and cloacal swabs were consistently negative in the
control group and positive in the challenged groups. PCR assays have a very high specificity
and sensitivity, but some of the concerns with this technology is artifact contamination, which
can result in false positives (Dorrestein 1993; Fudge 1997; Messmer, Tully et al. 2000; Ritchie
BW 2000; Vanrompay 2000). This artifact contamination is unlikely in our study, since all the
negative control birds remained negative. PCR assays detect only a target segment of an
organism’s nucleic acid; they do not routinely differentiate between nucleic acid that originated
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from a viable or non viable organism (Ritchie BW 2000). Therefore, interpretation of a positive
results, particularly in a patient that is asymptomatic, is limited to saying that the target segment
of nucleic acid was detected in the tested sample, not that the patient is or has been infected. In
the same way, when interpreting PCR-based results, the non-viable nucleic acid can persist in a
host for months following exposure, that many host exposed to an organism do not become
infected, and that the host infected can remain subclinical (Ritchie BW 2000). Thus, from the
PCR assay results, it can not be concluded that the the vaccine failed to prevent P. psittaci
excretion. For better evaluation of shedding of C. psittaci viable organism, culture from choanal
and cloacal swabs should be considered.
The lesions reported in the vaccinated groups were not significantly different from the
positive control. These lesions, identified mostly in the conjuntiva, liver and spleen, were only
mild to moderate. Since the negative control was vaccinated with the adenovirus itself, there was
not a placebo control that could be used to compare lesions. Histochemical or
immunohistochemical stainings, would have confirmed the presence of C. psittaci in the lesions
(OIE 2004).
The C. psittaci culture from pooled samples, were only positive for one from the adenoMOMP group and another from the MOMP DNA groups that died during the study. Culture is
considered “ the gold standard” for evaluating other methods, even thought it probably does not
have 100% sensitivity or specificity (Arizmendi and Grimes 1995). The main disadvantage of the
culture is the false negatives. In this study, samples from different tissues were submitted to
increase the sensitivity.
Future studies include a complete review of the material and methods of this study. The
birds for subsequent studies should be negative serological and by PCR assays against
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C.psittaci, since SPF cockatiles are not available. The inoculum should be evaluated prior to the
next study, and be able to produce severe clinical signs and mortality in positive control. The
strain of the C. psittaci organism as well as the strain of the MOMP used for the vaccine design,
should be determined. The vaccine virus should be sequenced to determined wether the MOMP
gene is present, and evaluated for MOMP expression in cell cultures and immunohistochemical
assays. The vaccines v titer should be determined by the method of 50% tissue culture infectious
dose. Serologic assays to detect specific MOMP antibodies should be developed, using rabbit
anti-cockatiel immunoglobulin G. Repeated conjuntival-choanal- cloacal swabs for cultures to
isolate C. psittaci organisms should be completed to assess shedding during the vaccine trial,
and organisms should be quantified. Immunohistochemistry should be performed on histologic
sections, and C .psittaci organism should be quantified within the lesions.
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CHAPTER SIX
CONCLUSIONS
A randomized controlled clinical trial to determine the efficacy of two recombinant
DNA vaccines against C. psittaci in cockatiels was completed. There was a failure to detect
antibody response by indirect immunofluorescent assay. The cockatiels developed mild clinical
signs and minimal mortality after challenge. The necropsy and histopathologic evaluation of the
tissues revealed mild to moderate lesions and no significant difference with positive control.
Further studies with reviewed materials and methods are needed to evaluate the efficacy of the
vaccines.
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